


15TH INTERNATIONAL MYELOMA WORKSHOP

SEPTEMBER 23-26, 2015

Rome, Auditorium Parco della Musica



PROGRAM

ORGANIZING COMMITTEE

Mario Boccadoro
Michele Cavo
Hermann Einsele
Antonio Palumbo
Pieter Sonneveld

UNDER THE AUSPICES OF THE INTERNATIONAL MYELOMA SOCIETY AND ITS BOARD OF DIRECTORS

Kenneth C. Anderson (President)
Jesús F. San Miguel (Vice-President)
Joan Bláde (Secretary)
Angela Dispenzieri (Treasurer)
Michel Attal
Hervé Avet-Loiseau
Meletios-Athanassios Dimopoulos
Sagar Lonial
Angelo Maiolino
Gareth J. Morgan
Nikhil C. Munshi
Hirokazu Murakami
Andrew Spencer

ITALIAN SCIENTIFIC COMMITTEE

Mario Boccadoro
Michele Cavo
Antonio Palumbo
Luca Baldini
Alessandro Corso
Francesco Di Raimondo
Fortunato Morabito
Pellegrino Musto
Massimo Offidani
Francesca Patriarca
Maria Teresa Petrucci
Patrizia Tosi

NURSE ORGANIZING COMMITTEE

Beth Faiman
Tracy King
Monica Morris
Elena Ponticelli
Tiffany Richards

WELCOME MESSAGE

Dear Colleagues and Friends,

It is my great pleasure and honor to invite you to attend the 15th International Myeloma Workshop to be held in Rome, Italy, from September 23rd to 26th, 2015. During this important biannual event, the emerging advances in the biology and treatment of multiple myeloma, as well as debates on more controversial arguments, and consensus report will be presented.

The location of the Workshop, in the Auditorium Parco della Musica which is right in the city centre, will ensure that you all enjoy both the meeting and the fascinating city of Rome.

I am very much looking forward to welcoming you to Rome in September 2015!



Antonio Palumbo
President, 15th International Myeloma Workshop

AUSPICES

Con l'adesione del Presidente della Repubblica Italiana
Under the patronage of the President of the Italian Republic

Ministero della Salute
Italian Ministry of Health

TIMETABLE

Wednesday, September 23, 2015		Thursday, September 24, 2015		Friday, September 25, 2015		Saturday, September 26, 2015	
07.00-08.00		07.00-08.00 MEET THE EXPERTS	07.00-08.00 MEET THE EXPERTS	07.00-08.00 MEET THE EXPERTS	07.00-08.00 MEET THE EXPERTS		
08.00-09.00		08.00-10.20 NEWLY DIAGNOSED MULTIPLE MYELOMA YOUNG PATIENTS	08.00-10.20 NEWLY DIAGNOSED MULTIPLE MYELOMA YOUNG PATIENTS	08.00-10.20 NEWLY DIAGNOSED MULTIPLE MYELOMA ELDERLY PATIENTS	08.00-09.00 DEBATE		
09.00-10.00	09.30-09.45 OPENING CEREMONY				09.00-10.00 RISING STARS AWARD		
	09.45-10.30 ROBERT KYLE LECTURE	10.20-10.50 Coffee Break	10.20-10.50 Coffee Break	10.20-10.50 Coffee Break	10.00-10.15 BART BARLOGIE YOUNG INVESTIGATOR AWARD		
10.00-11.00	10.30-11.00 How to introduce Technology Assessment in Clinical Studies	10.50-12.20 PRIME ONCOLOGY SPONSORED SYMPOSIUM supported by TAKEDA ONCOLOGY Building on the Foundation of Proteasome Inhibition in Multiple Myeloma	10.50-12.20 PRIME ONCOLOGY SPONSORED SYMPOSIUM supported by TAKEDA ONCOLOGY Building on the Foundation of Proteasome Inhibition in Multiple Myeloma	10.50-12.20 CELGENE CORPORATION SPONSORED SYMPOSIUM The Role of Immunomodulators in the Future Landscape of Multiple Myeloma	10.30-11.00 DEBATE		
11.00-12.00	11.00-13.00 GENOMICS AND MICROENVIRONMENT				11.00-12.30 PLENARY ABSTRACT SESSION		
12.00-13.00		12.20-13.20 Lunch	12.20-13.20 Lunch	12.20-13.20 Lunch	12.30-13.00 CLOSING CEREMONY		
13.00-14.00	13.00-14.00 Lunch	13.20-14.50 AMGEN SPONSORED SYMPOSIUM Delving Into the Deep – Advances in the Treatment of Multiple Myeloma in 2015	13.20-14.50 AMGEN SPONSORED SYMPOSIUM Delving Into the Deep – Advances in the Treatment of Multiple Myeloma in 2015	13.20-14.50 JANSSEN SPONSORED SYMPOSIUM The Clinical Rationale and Experience with Monoclonal Antibodies in Multiple Myeloma	13.00-14.00 Lunch		
14.00-15.00	14.00-16.00 DIAGNOSTIC AND RESPONSE CRITERIA						
15.00-16.00		14.50-16.30 RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS	14.50-16.30 RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS	14.50-16.30 IMMUNOTHERAPY			
16.00-17.00	16.00-16.30 Coffee Break	16.30-17.00 Coffee Break	16.30-17.00 Coffee Break	16.30-17.00 Coffee Break	16.30-17.00 Coffee Break		
17.00-18.00	16.30-18.00 NOVARTIS ONCOLOGY SPONSORED SYMPOSIUM Understanding the Role of Epigenetics in the Pathogenesis and Treatment of Multiple Myeloma	17.00-18.40 ALLOGENEIC TRANSPLANTATION AND NOVEL AGENTS	17.00-18.40 ALLOGENEIC TRANSPLANTATION AND NOVEL AGENTS	17.00-18.40 SPECIAL CONDITIONS			
18.00-19.00	18.00-18.45 Waldenström's Award	18.40-19.40 POSTER SESSION I	18.40-19.40 POSTER SESSION I	18.40-19.40 POSTER SESSION II			
19.00-20.00	18.45-19.15 Patient Association Talks						
	19.15-19.30 IMS General Assembly						
20.00-21.00	19.30-21.30 Welcome Reception						

FACULTY

Kenneth C.	Anderson	Boston, USA	Alessandra	Larocca	Torino, Italy
Michel	Attal	Toulouse, France	Xavier	Leleu	Lille, France
Daniel	Auclair	Norwalk, USA	Sagar	Lonial	Atlanta, USA
Hervé	Avet-Loiseau	Toulouse, France	Heinz	Ludwig	Vienna, Austria
David E.	Avigan	Boston, USA	Angelo	Maiolino	Rio de Janeiro, Brazil
Nizar J.	Bahlis	Calgary, Canada	Fabio	Malavasi	Torino, Italy
Luca	Baldini	Milano, Italy	Thomas G.	Martin	San Francisco, USA
Bart	Barlogie	New York, USA	Maria-Victoria	Mateos	Salamanca, Spain
Leif P.	Bergsagel	Scottsdale, USA	Philip L.	McCarthy	Buffalo, USA
Joan	Bladé	Barcelona, Spain	Giampalolo	Merlini	Pavia, Italy
Mario	Boccardo	Torino, Italy	Fortunato	Morabito	Cosenza, Italy
Lawrence	Boise	Atlanta, USA	Philippe	Moreau	Nantes, France
Sara	Bringham	Torino, Italy	Gareth J.	Morgan	Little Rock, USA
Jamie	Cavenagh	London, UK	Nikhil C.	Munshi	Boston, USA
Michele	Cavo	Bologna, Italy	Hirokazu	Murakami	Maebashi, Japan
Raymond L.	Comenzo	Boston, USA	Pellegrino	Musto	Rionero in Vulture (PZ), Italy
Alessandro	Corso	Pavia, Italy	Ruben	Niesvizky	New York, USA
Carlo	Croce	Columbus, USA	Susie	Novis	Hollywood, USA
Faith	Davies	Little Rock, USA	Massimo	Offidani	Ancona, Italy
Francesco	Di Raimondo	Catania, Italy	Robert Z.	Orlowski	Houston, USA
Angela	Dispenzieri	Rochester, USA	Bruno	Paiva	Pamplona, Spain
Brian	Durie	Los Angeles, USA	Antonio	Palumbo	Torino, Italy
Hermann	Einsele	Würzburg, Germany	Francesca	Patriarca	Udine, Italy
Monika	Engelhardt	Freiburg, Germany	Maria Teresa	Petrucci	Roma, Italy
Thierry	Facon	Lille, France	Torben	Plesner	Vejle, Denmark
Jean-Paul	Ferland	Paris, France	Felipe	Prósper	Pamplona, Spain
Rafael	Fonseca	Scottsdale, USA	Noopur	Raje	Boston, USA
Francesca	Gay	Torino, Italy	S. Vincent	Rajkumar	Rochester, USA
Morie A.	Gertz	Rochester, USA	Paul G.	Richardson	Boston, USA
Irene M.	Ghobrial	Boston, USA	Jesús F.	San Miguel	Pamplona, Spain
Sergio A.	Giralt	New York, USA	Jatin J.	Shah	Houston, USA
Hartmut	Goldschmidt	Heidelberg, Germany	Kazuyuki	Shimizu	Kakamigahara, Japan
Roman	Hájek	Ostrava, Czech Republic	Pieter	Sonneveld	Rotterdam, The Netherlands
Jean-Luc	Harousseau	Saint Denis La Plaine, France	Andrew	Spencer	Melbourne, Australia
Jian	Hou	Shanghai, China	Edward A.	Stadtmauer	Philadelphia, USA
Cynthia	Iglesias	York, United Kingdom	A. Keith	Stewart	Scottsdale, USA
Tadao	Ishida	Sapporo, Japan	Evangelos	Terpos	Athens, Greece
Sudar	Jagannath	New York, USA	Patrizia	Tosi	Rimini, Italy
Andrzej	Jakubowiak	Chicago, USA	Steven P.	Treon	Boston, USA
Nicolaus	Kroeger	Hamburg, Germany	Niels	van den Donk	Amsterdam, The Netherlands
Shaji K.	Kumar	Rochester, USA	Elena	Zamagni	Bologna, Italy
Robert	Kyle	Rochester, USA	Jeffrey A.	Zonder	Detroit, USA
C. Ola	Landgren	New York, USA	Sonja	Zweegman	Amsterdam, The Netherlands



CONGRESS INFORMATION

VENUE

Auditorium Parco della Musica
 Viale de Coubertin, 30
 00196 Rome (Italy)
www.auditorium.com

HOW TO REACH

The Auditorium Parco della Musica of Rome is in Viale Pietro de Coubertin, near the Palazzetto dello Sport.
 The Auditorium Parco della Musica is in the Flaminio district of Rome, by the Villaggio Olimpico and can be easily reached by public transport:

Bus Routes

- 910, from Termini Station and Piazza Mancini
- 53, from Piazza Mancini and Piazza San Silvestro
- 217, from Viale XVII Olimpiade and Termini Station
- 231, from Piazza Mancini and Piazzale Canestre (in Villa Borghese park). Only weekends
- Linea "M", special bus route between Termini station and Viale Pietro de Coubertin Auditorium stop. From 17h 00 - every 15 mins. Last bus from the Auditorium departs at the end of last event.

Tram routes

- 2, from Piazzale Flaminio and Piazza Mancini

Trains

- Metro A line to the Flaminio stop then no.2 tram
- Or the Ferrovia Roma-Nord train to the Piazza Euclide stop


By car

- From the G.R.A. (ring-road around Rome) take the Flaminio Saxa Rubra exit towards Corso di Francia
- From the Lungotevere Flaminio turn off into Viale Tiziano and then again at the Palazzetto dello Sport.

PARKING AREA

There are large car parking facilities by the Auditorium Parco della Musica with designated areas for disabled visitors.

AUDITORIUM PARCO DELLA MUSICA PARKING and BUS STOP



HOTEL AND SHUTTLE INFORMATION DESK

The congress will provide complimentary transfer service between the hotels booked through the IMW hotel booking office and the Auditorium Parco della Musica.

Transfer services will run according to the meeting schedule. One ride in the morning and one in the evening. Please look for detailed shuttle bus schedules in your hotel lobby and on the website (www.imw2015.it).

For further information about hotel accommodation and shuttle bus service provided by the meeting please visit the Hotel and Shuttle Information Desk. The desk is located in the Registration Area and will be open during the following hours:

<u>Wednesday, September 23, 2015</u>	8.00 - 19.00
<u>Thursday, September 24, 2015</u>	8.00 - 19.00
<u>Friday, September 25, 2015</u>	8.00 - 19.00
<u>Saturday, September 26, 2015</u>	8.00 - 14.00

ROME INFORMATION DESK

For all the information about the city (guided tours, museums, public transportation, etc.), please visit the Rome Information Desk. The desk is located near the bar and will be open during the following hours:

Wednesday, September 23, 2015	8.00 - 19.00
Thursday, September 24, 2015	8.00 - 19.00
Friday, September 25, 2015	8.00 - 19.00
Saturday, September 26, 2015	8.00 - 14.00

REGISTRATION FEES

Registration Categories	Onsite Registration
IMS Members	€ 650,00
Non-Member	€ 800,00
Nurses	€ 200,00
Exhibitors	€ 800,00

The registration fee includes:

- Participation in the scientific sessions
- Access to the exhibition area
- Conference kit
- Attendance certificate
- Lunches
- Coffee breaks
- Welcome reception
- Abstracts e-book

REGISTRATION HOURS

INDIVIDUALS and EXHIBITORS

Tuesday, September 22, 2015	17.00 - 20.00
Wednesday, September 23, 2015	7.00 - 18.00
Thursday, September 24, 2015	7.00 - 18.00
Friday, September 25, 2015	7.00 - 18.00
Saturday, September 26, 2015	7.00 - 13.00

MEET THE EXPERTS

Tuesday, September 22, 2015	8.30 - 20.00
Wednesday, September 23, 2015	7.00 - 18.00
Thursday, September 24, 2015	7.00 - 18.00
Friday, September 25, 2015	7.00 - 18.00

NURSE

Tuesday, September 22, 2015	17.00 - 20.00
Wednesday, September 23, 2015	7.00 - 10.00

GROUPS & EXHIBITORS

Tuesday, September 22, 2015	8.30 - 16.30
-----------------------------	--------------

BADGE

Badges and meeting materials will be given at the counters in the registration area (ground floor of the Auditorium Parco della Musica). Remember to print and to bring with you in Rome the invitation letter and the badge barcode you received in the "Registration Info" automatic e-mail.

All registered participants, speakers, exhibitors and press staff, will be given a badge which must be worn in order to be admitted to the scientific sessions. **Badge is mandatory to enter the congress area.**

A self-printing system will be available in the Registration Area. Delegates, nurses and exhibitors will be able to collect their badges simply by having their personal barcode scanned by the optical reader at the self-printing machines. Speakers and press staff are kindly requested to collect their badges at the Registration desk.

The barcode on the badge stores the following personal information: name, surname, country and email address provided at the time of registration. It can be used by exhibitors to register visitors to their booths and to send additional information on their products and services.



ATTENDANCE CERTIFICATE

Delegates, nurses and speakers will be able to collect the attendance certificates by having their personal barcode read at the self-printing machines.

The service will be available from September 23, 2015 evening.

CLOAKROOM AND LUGGAGE

In the cloakroom you can leave your belongings free of charge.

The cloakroom is located in the Registration Area and will be open at the following hours:

Wednesday, September 23, 2015	6.30 - 21.30
Thursday, September 24, 2015	6.30 - 20.00
Friday, September 25, 2015	6.30 - 20.00
Saturday, September 26, 2015	6.30 - 14.00

CATERING

Lunches, coffee breaks and welcome cocktail are included in the registration fee. No coupon is needed.

Opening hours:

Wednesday, September 23, 2015	Lunch	13.00 - 14.00
	Coffee Break	16.00 - 16.30
Thursday, September 24, 2015	Coffee Break	10.20 - 10.50
	Lunch	12.20 - 13.20
	Coffee Break	16.30 - 17.00
Friday, September 25, 2015	Coffee Break	10.20 - 10.50
	Lunch	12.20 - 13.20
	Coffee Break	16.30 - 17.00
Saturday, September 26, 2015	Coffee Break	10.15 - 10.30
	Lunch	13.00 - 14.00

The **IMW Welcome Cocktail** is scheduled on September 23, 2015 from 19.30 to 21.30 in the Cavea area. It is an outdoor standing buffet dinner.

The bar is located near the Exhibition Area and it will be open at the following hours:

Tuesday, September 22, 2015	8.00 - 19.30
Wednesday, September 23, 2015	6.30 - 19.30
Thursday, September 24, 2015	6.30 - 19.30
Friday, September 25, 2015	6.30 - 19.30
Saturday, September 26, 2015	6.30 - 19.30

Direct payment in Euro.

PHOTOS AND AUDIO-VIDEO RECORDING

Individual photos and audio-video recording are prohibited.

Only authorized staff can provide photos and audio-video recording services.

INTERNET ACCESS

WiFi is available inside the Congress Area as follows:

ID: IMW2015

PASSWORD: TAKEDA2015

An internet point will be available in the Exhibition area (see floor plan).

CASH WITHDRAWAL

A cash dispenser is located at the entrance of the meeting venue. Onsite payments should be made in Euro.

EXHIBITION

The exhibition area will be open at the following hours:

Wednesday, September 23, 2015	9.00 - 21.00
Thursday, September 24, 2015	8.00 - 19.00
Friday, September 25, 2015	8.00 - 19.00
Saturday, September 26, 2015	8.00 - 14.00



EXHIBITION AREA

SPONSOR

- Amgen
- Amgen Business Suite
- Amgen Meeting Site
- Bristol-Myers Squibb Co.
- Celgene Corporation
- Celgene Corporation Hospitality Suite
- Doctors.MD Ltd.
- IMS - International Myeloma Society
- Janssen
- Novartis Therapeutics Inc.
- Novartis Myeloma
- Novartis Oncology
- Novartis Oncology Hospitality Suite
- Takeda Oncology
- Takeda Oncology Staff Office
- 15th International Myeloma Workshop

AREA

- B1
- B2
- 13
- G
- C1-D1
- C2-D2
- 8
- 10
- F
- 3
- 2
- 4-5-6-E1
- E2
- A1
- A2
- 9

MEETING ROOMS

SPONSOR


- Amgen
- Bristol-Myers Squibb Co.
- Bristol-Myers Squibb Co.
- Celgene Corporation
- Celgene Corporation
- Janssen
- Takeda Oncology
- Takeda Oncology
- Takeda Oncology

- ROOM B
- ROOM B
- ROOM E
- ROOM C
- ROOM D
- ROOM A
- ROOM A
- STUDIO 1
- STUDIO 2
- STUDIO 3

TEATRO STUDIO HALL

NURSING SYMPOSIUM

MEET THE EXPERTS SESSIONS



SANTA CECILIA HALL

PLENARY SESSION

FLOOR PLAN

SCIENTIFIC INFORMATION

LANGUAGE

The Workshop will be in English with no simultaneous translation into other languages.

ITALIAN CME CREDITS

Two Italian CME applications have been submitted as follows:

Main program (September 23-24-25-26, 2015):

- Provider Studio ER Congressi SRL: ID 828-132558.
- **No. 11 CME credits for Physicians** (Clinical Biochemistry, Cardiac Surgery, Cardiology, General Surgery, Palliative Care, Haematology, Epidemiology, Pharmacology and Clinical Toxicology, Medical Genetics, Geriatrics, Laboratory of Medical Genetics, General Medicine, Internal Medicine, Nuclear Medicine, Microbiology and Virology, Oncology, Clinical Pathology, Radiotherapy), **Biologists, Medical Laboratory Scientists, Nurses and Chemists**.

- Educational objective: "guidelines-protocols-procedures".
 Poster sessions, meet the experts sessions, sponsored symposia are not included in the submission.

In order to claim for credits attendees should:

- wear a magnetic tag in order to register their presence inside the Plenary Hall. Please ask for it at the CME Registration Desk;
- attend at least the 80% of the submitted program;
- complete the CME questionnaire. Please ask for it at the CME Registration Desk on Saturday 26, 2015 morning;
- return the magnetic tag and the questionnaire at the end of the meeting.

Nursing Symposium (September 23, 2015):

- Provider Studio ER Congressi SRL: ID 828-132580.
- **No. 5 CME credits for Nurses**.
- Educational objective: "guidelines-protocols-procedures".

In order to claim for credits nurses should:

- sign the attendance list at the entrance of the Teatro Studio Hall;
- attend the 100% of the Nursing Symposium;
- complete the CME questionnaire. Please ask for it at the entrance of the Teatro Studio Hall on Wednesday 23, 2015 afternoon;
- return the questionnaire at the end of the Nursing Symposium

EBAH CME CREDITS

The program of the "15th International Myeloma Workshop" has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for **no. 25 CME credits** for Physicians, Biologists, Medical Laboratory Scientists, Nurses and Chemists. EBAH Credit Points will be awarded for the Plenary Sessions and Meet the Experts Sessions.

To request credits, please fill out the form and return it to the registration desk at the end of the meeting.

We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: <http://ebach.org> even on site.

TEXT MESSAGE AND VOTING FLAGS

Text message system is available during the whole meeting in order to improve discussion during the plenary sessions.

Voting green/red flags for the Debate sessions are available inside the Plenary Hall in order to improve the interaction between attendees and speakers.

POSTER AREA

Poster sessions will take place in the Poster Area.

Opening hours:

Installation	Wednesday, September 23, 2015	14.00 - 19.00
Viewing	Thursday, September 24, 2015	8.00 - 20.00
	Friday, September 25, 2015	8.00 - 20.00
Best Poster Discussion	Saturday, September 26, 2015	8.00 - 13.00
	Thursday, September 24, 2015	18.40 - 19.40
	Friday, September 25, 2015	18.40 - 19.40
Tear off	Saturday, September 26, 2015	13.00 - 14.00

Posters should be installed/removed during the indicated set-up time (see above). Materials to hang posters will be available at the poster area. The Congress provides one board for each poster; the author is responsible for hanging and for removing the poster. Please note that the organisers do not take any responsibility for returning uncollected material to the authors. There will be a poster helpdesk in the poster area where staff will be happy to assist you.

Posters will be on display in the Poster Area for three days and will be open for viewing on Thursday, Friday and Saturday.

The best posters will be presented during Poster walking session on Thursday and Friday from 18.40 to 19.40.



SLIDE CENTER/SPEAKERS' AREA

Opening hours:

Wednesday, September 23, 2015	7.30 - 19.00
Thursday, September 24, 2015	6.30 - 19.00
Friday, September 25, 2015	6.30 - 19.00
Saturday, September 26, 2015	6.30 - 14.00

MEET THE EXPERTS SESSIONS

There will be four Meet the Experts Sessions on September 24, September 25 and September 26 from 7.00 to 8.00. The registration is not included in the Registration Fee.

It costs Euro 25,00 per day (VAT included). Each session is restricted to 25 participants.

Preregistration for these sessions is necessary. Tickets can also be purchased during registration hours at the Registration Desk if still available.

All Meet the Expert Sessions are located in TEATRO STUDIO HALL as follows:

Thursday, Sep 24, 2015	Friday, Sep 25, 2015	Saturday, Sep 26, 2015
Diagnostic Criteria Xavier Leloux, Elena Zamagni GREEN ROOM	Monoclonal Gammopathy of Undetermined Significance - Smoldering Multiple Myeloma Luca Baldini, Brian G.M. Durie GREEN ROOM	Amyloid Light-chain Amyloidosis Raymond L. Comenzo, Fortunato Morabito GREEN ROOM
Newly Diagnosed Multiple Myeloma Patients < 65 years, High-risk Patients: How to treat Michele Cavo, Francesca Patriarca RED ROOM	Newly Diagnosed Multiple Myeloma Fit Patients > 65 years: How to treat Ruben Nlesvizky, Massimo Offidani RED ROOM	Waldenström Macroglobulinemia Pellegrino Musto, Steven P. Treon RED ROOM
Newly Diagnosed Multiple Myeloma Patients < 65 years, Low-risk Patients: How to treat Mario Boccadoro, Andrzej J. Jakubowiak BLUE ROOM	Newly Diagnosed Multiple Myeloma Frail Patients > 65 years: How to treat Sara Brington, Sonja Zweggman BLUE ROOM	Bone Disease Noopur Rajje, Patrizia Tosi BLUE ROOM
Relapsed/Refractory Multiple Myeloma 1-3 Previous Lines of Therapy: How to treat Faith E. Davies, Francesco Di Raimondo YELLOW ROOM	Relapsed/Refractory Multiple Myeloma 4-6 Previous Lines of Therapy: How to treat Alessandro Corso, Susana Lopez-Garcia YELLOW ROOM	Supportive Care Joan Bledé, Maria Teresa Petrucci YELLOW ROOM

AWARDS

WALDENSTRÖM'S AWARD

Recognition for a lifetime achievement for contributions to multiple myeloma research. The award is named for Professor Jan Waldenström, who was a pioneer in treating blood cancers. The award presentation is scheduled on September 23, 2015 at 18.00 in the Plenary Session.

RISING STARS AWARD

The Scientific Committee selected the best four abstracts submitted by authors under 35 years of age. These abstracts will be presented in plenary session on Saturday from 9.00 to 10.00. The authors will receive a check of Euro 5,000,00 onsite.

BART BARLOGIE YOUNG INVESTIGATOR AWARD

In recognition to the outstanding research developed by Dr. Bart Barlogie in the field of multiple myeloma, the IMS Board of Directors decided to establish the Bart Barlogie Young Investigator Award. This award is aimed at formally recognizing and stimulating excellence in myeloma research. The Young Investigator Award will be given to an investigator under the age of 40 years in recognition of their research in the myeloma field. An Award of US \$25,000 by the IMS will be given at each of the International Myeloma Workshops, beginning with Rome in September 2015.

The award presentation is scheduled on September 26, 2015 at 10.00 in the Plenary Session.

IMW APP

A special mobile app has been developed for this congress in which you can find the entire program and further information. Use the app to find sessions of interest, create your own program, find and read all the abstracts.

Download the "IMW2015" app from the Apple App store or Google-Play.

OFFICIAL WEBSITE

www.imw2015.it

CHANGES

Parts of the program may be changed without prior notice.



SERVICES PROVIDED

Service	Name	Location
Abstract e-book	Congress Kit	Registration Area
Cash Withdrawal	Cash Dispenser	Meeting Venue Entrance
City Information	Rome Information Desk	Exhibition Area
Cloakroom and Luggage	Cloakroom	Registration Area
Internet	Internet Point	Exhibition Area
WiFi	Wireless Internet	Throughout the Venue
Exhibition Information	Exhibitor Help Desk	Exhibition Area
Hotel and Shuttle Information	Hotel and Shuttle Information Desk	Registration Area
Meet the Experts Tickets	Registration Desk	Registration Area
Vatican Museum Tickets	Registration Desk	Registration Area
Poster Information	Poster Help Desk	Poster Area



15TH INTERNATIONAL MYELOMA WORKSHOP

SEPTEMBER 23 - 26, 2015

Rome, Auditorium Parco della Musica

OPENING HOURS

	Tuesday, September 22, 2015	Wednesday, September 23, 2015	Thursday, September 24, 2015	Friday, September 25, 2015	Saturday, September 26, 2015
Registration Area	8.30 - 20.00	6.30 - 20.00	6.30 - 20.00	6.30 - 20.00	6.30 - 14.00
Slide Center/Speakers' Area		7.30 - 19.00	6.30 - 19.00	6.30 - 19.00	6.30 - 14.00
Cloakroom		6.30 - 21.30	6.30 - 20.00	6.30 - 20.00	6.30 - 14.00
Exhibition Area		9.00 - 21.00	8.00 - 19.00	8.00 - 19.00	8.00 - 14.00
Poster Area			8.00 - 20.00	8.00 - 20.00	8.00 - 13.00
Rome Information Desk		8.00 - 19.00	8.00 - 19.00	8.00 - 19.00	8.00 - 14.00
Hotel and Shuttle Info Desk		8.00 - 19.00	8.00 - 19.00	8.00 - 19.00	8.00 - 14.00
Bar	8.00 - 19.30	6.30 - 19.30	6.30 - 19.30	6.30 - 19.30	6.30 - 19.30

www.imw2015.com

Wednesday, September 23, 2015

09.30-09.45 **OPENING CEREMONY**

SANTA CECILIA HALL

Chairmen: Robert Kyle, Antonio Palumbo



09.45-10.30 **ROBERT KYLE LECTURE**

Access to Innovation and Quality of Care in the Context of Economic Constraints: a Challenge for Healthcare
Jean-Luc Harousseau

10.30-11.00

How to introduce Technology Assessment in Clinical Studies
Cynthia Iglesias

GENOMICS AND MICROENVIRONMENT

SANTA CECILIA HALL



Chairmen: Gareth J. Morgan, Nikhil C. Munshi

11.00-11.20

Next Generation Sequencing
Nikhil C. Munshi

11.20-11.40

Gene Expression Profile
Pieter Sonneveld

11.40-12.00

SNP/microRNA
Carlo Croce

12.00-12.20

The Vk*MYC Mouse Model to study Drug and Immunotherapy Response and Resistance
P. Leif Bergsagel

12.20-12.40

Multiple Myeloma Biological Pathways
Gareth J. Morgan

12.40-13.00

Multiple Myeloma and Bone Marrow Niche
Irene M. Ghobrial

13.00-14.00

Lunch

EXHIBITION AREA

DIAGNOSTIC AND RESPONSE CRITERIA



SANTA CECILIA HALL

Chairmen: Hervé Avet-Loiseau, S. Vincent Rajkumar

14.00-14.20

New Diagnostic Criteria for Multiple Myeloma
S. Vincent Rajkumar

14.20-14.40

Flow Cytometry for Minimal Residual Disease
Bruno Paiva

14.40-15.00

Next Generation Sequencing for Minimal Residual Disease
Hervé Avet-Loiseau

15.00-15.20

Imaging Techniques
Elena Zamagni

15.20-15.40

Risk Assessment and Stratification
Rafael Fonseca

15.40-16.00

Geriatric Assessment and Stratification
Alessandra Larocca

16.00-16.30

Coffee break

EXHIBITION AREA

NOVARTIS ONCOLOGY SPONSORED SYMPOSIUM
Understanding the Role of Epigenetics in the Pathogenesis and Treatment of Multiple Myeloma

Chairman: Jesús F. San Miguel

SANTA CECILIA HALL

16.30-16.40

Welcome and Opening Remarks
Jesús F. San Miguel

16.40-16.55

Introduction to Epigenetics and its Role in the Pathogenesis of Hematologic Malignancies
Felipe Prósper

16.55-17.15

Rationale for Targeting Epigenetic Mechanisms in Multiple Myeloma
Andrew Spencer

Thursday, September 24, 2015

17.15-17.35 **Clinical Update on Pan-Deacetylase Inhibitors in Multiple Myeloma**

Jamie D. Cavenagh

17.35-17.55 **Opportunities for Novel Combinations with Agents Targeting**

Epigenetic Mechanisms

Hermann Einsele

17.55-18.00 **Closing Remarks**

Jesús F. San Miguel

Chairmen: Kenneth C. Anderson, Robert Kyle



SANTA CECILIA HALL

18.00-18.45 **Waldenström's Award**

18.45-19.15 **Patient Association Talks**

- **International Myeloma Foundation**

Susie Novis

- **Multiple Myeloma Research Foundation**

Daniel Auclair

19.15-19.30 **IMS General Assembly**

19.30-21.30 *Welcome Reception*

CAVEA AREA

MEET THE EXPERTS



Simultaneous sessions in four rooms

07.00-08.00 **Diagnostic Criteria**

Xavier Leleu, Elena Zamagni

07.00-08.00 **Newly Diagnosed Multiple Myeloma Patients < 65 years,**

High-risk Patients: How to treat

Michele Cavo, Francesca Patriarca

07.00-08.00 **Newly Diagnosed Multiple Myeloma Patients < 65 years,**

Low-risk Patients: How to treat

Mario Boccadoro, Andrzej J. Jakubowiak

07.00-08.00 **Relapsed/Refractory Multiple Myeloma 1-3 Previous**

Lines of Therapy: How to treat

Faith E. Davies, Francesco Di Raimondo

TEATRO STUDIO HALL

GREEN ROOM

RED ROOM

BLUE ROOM

YELLOW ROOM

NEWLY DIAGNOSED MULTIPLE MYELOMA YOUNG PATIENTS

Chairmen: Michele Cavo, Angelo Maiolino

08.00-08.20 **Optimal Induction**

Michel Attal

08.20-08.40 **Single-tandem Transplantation**

Hermann Einsele

08.40-09.00 **Optimal Consolidation Therapy**

Michele Cavo

09.00-09.20 **Transplant Eligible Maintenance**

Philip L. McCarthy

09.20-09.40 **Ongoing Studies/Open Questions in America**

Sergio A. Giralt

09.40-10.00 **Ongoing Studies/Open Questions in Europe**

Roman Hájek

10.00-10.20 **Ongoing Studies/Open Questions in Asia Pacific**

Jian Hou



SANTA CECILIA HALL

PRIME ONCOLOGY SPONSORED SYMPOSIUM

Supported by TAKEDA ONCOLOGY

Building on the Foundation of Proteasome Inhibition in Multiple Myeloma

Chairman: Mario Boccadoro

- 10.50-10.52 **Welcome and Introduction**
Mario Boccadoro
- 10.52-10.55 **"Myeloma Guru" Questions**
- 10.55-11.10 **Targeting the Ubiquitin-proteasome System in Multiple Myeloma: Examining the Roots of Success**
Paul G. Richardson
- 11.10-11.15 **"Myeloma Guru" Questions**
- 11.15-11.30 **Challenges and Solutions with First-generation Proteasome Inhibition: Practical Strategies**
Maria-Victoria Mateos
- 11.30-11.35 **"Myeloma Guru" Questions**
- 11.35-11.50 **Second-generation Proteasome Inhibition: What a Difference a Generation makes**
Mario Boccadoro
- 11.50-11.55 **"Myeloma Guru" Questions**
- 11.55-12.10 **Implications of Oral Proteasome Inhibition: Impact on Patients**
Shaji K. Kumar
- 12.10-12.20 **Audience Questions and Faculty Panel Discussion**
- 12.20 **Adjourn**
- 12.20-13.20 **Lunch**

EXHIBITION AREA

AMGEN SPONSORED SYMPOSIUM

Delving Into the Deep - Advances in the Treatment of Multiple Myeloma in 2015

Chairman: Antonio Palumbo

- 13.20-13.25 **Welcome and Introduction**
Antonio Palumbo
- 13.25-13.42 **Reaching Beyond Overall Response in Patients with Multiple Myeloma**
Philippe Moreau
- 13.42-13.59 **Two-drug Combinations in the Treatment of Multiple Myeloma**
Evangelos Terpos
- 13.59-14.16 **Three-drug Combinations in the Treatment of Multiple Myeloma**
A. Keith Stewart
- 14.16-14.33 **The Evolving Role of Proteasome Inhibition in Multiple Myeloma**
Antonio Palumbo
- 14.33-14.48 **Panel Discussion**
- 14.48-14.50 **Summary and Close**
Antonio Palumbo

RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS

Chairmen: Joan Bladé, Sundar Jagannath

- 14.50-15.10 **How I treat Relapsed/Refractory Multiple Myeloma, Sequence Strategy, Patient Selection**
Robert Orłowski
- 15.10-15.30 **How I treat Refractory Disease and Extramedullary Disease**
Joan Bladé
- 15.30-15.50 **How I treat Serious Adverse Events**
Heinz Ludwig
- 15.50-16.10 **How I use Bone Support**
Evangelos Terpos
- 16.10-16.30 **How I use Supportive Care and Palliation**
Francesca Gay

SANTA CECILIA HALL

SANTA CECILIA HALL



SANTA CECILIA HALL

ALLOGENEIC TRANSPLANTATION AND NOVEL AGENTS

Chairmen: Nicolaus Kroeger, Andrew Spencer

17.00-17.20 **Significance of Allogenic Stem Cell Transplantation**

Nicolaus Kroeger

17.20-17.40 **Selective Histone Deacetylase Inhibitor**

Noopur Rajee

17.40-18.00 **Inhibitors (KPT – KSP)**

Jatin J. Shah

18.00-18.20 **Inhibitors (BCL2 – MCL1 – CDK)**

Lawrence Boise

18.20-18.40 **Targeting Oncogenic Pathways in Myeloma (MEK – PI3K – AKT)**

Andrew Spencer

POSTER SESSION I

18.40-19.40

Multiple Myeloma Genomics, Diagnosis, Prognosis, Imaging

Chairman: Nizar J. Bahlis

18.40-19.40

Multiple Myeloma Therapy in Newly Diagnosed Patients including Transplantation

Chairman: Andrzej J. Jakubowiak

18.40-19.40

Epidemiology, QoL, Toxicities, and Other Plasma Cell Dyscrasias

Chairman: Raymond L. Comenzo

Friday, September 25, 2015

MEET THE EXPERTS

Simultaneous sessions in four rooms

07.00-08.00

Monoclonal Gammopathy of Undetermined Significance - Smoldering Multiple Myeloma

Luca Baldini, Brian G.M. Durie

07.00-08.00

Newly Diagnosed Multiple Myeloma Fit Patients > 65 years: How to treat

Ruben Niesvizky, Massimo Offidani

07.00-08.00

Newly Diagnosed Multiple Myeloma Frail Patients > 65 years: How to treat

Sara Bringham, Sonja Zweegman

07.00-08.00

Relapsed/Refractory Multiple Myeloma 4-6 Previous Lines of Therapy: How to treat

Alessandro Corso, Sundar Jagannath

NEWLY DIAGNOSED MULTIPLE MYELOMA ELDERLY PATIENTS

Chairmen: Hirokazu Murakami, Paul G. Richardson

08.00-08.20

Debate - Change Therapy for High/Low Risk Patients - Yes

S. Vincent Rajkumar

08.20-08.40

Debate - Change Therapy for High/Low Risk Patients - No

Paul G. Richardson

08.40-09.00

Optimal Therapy for Fit Elderly Patients

Ruben Niesvizky

09.00-09.20

Optimal Therapy for Unfit Elderly Patients

Sonja Zweegman

09.20-09.40

Ongoing Studies/Open Questions in America

Morie A. Gertz

TEATRO STUDIO HALL

GREEN ROOM

RED ROOM

BLUE ROOM

YELLOW ROOM

EMEA
EMA
SANTA CECILIA HALL

POSTER AREA

09.40-10.00 **Ongoing Studies/Open Questions in Europe**
Monika Engelhardt

10.00-10.20 **Ongoing Studies/Open Questions in Asia Pacific**
Tadao Ishida

10.20-10.50 *Coffee break* EXHIBITION AREA

CELGENE CORPORATION SPONSORED SYMPOSIUM

The Role of Immunomodulators in the Future Landscape of Multiple Myeloma

Chairman: Michele Cavo

10.50-10.55 **Welcome**
Michele Cavo

10.55-11.15 **Multiple Myeloma – Coping with a Disrupted Immune Environment**
Kenneth C. Anderson

11.15-11.30 **Continuous Therapy for Elderly Newly Diagnosed Multiple Myeloma**
Thierry Facon

11.30-11.45 **Clonal Evolution – Disease Challenges**
Gareth J. Morgan

11.45-12.10 **IMiD-based Triplet Therapy for Multiple Myeloma**
Sagar Lonial

12.10-12.20 **Questions and Discussion**

12.20-13.20 *Lunch* EXHIBITION AREA

JANSSEN SPONSORED SYMPOSIUM

The Clinical Rationale and Experience with Monoclonal Antibodies in Multiple Myeloma

Chairmen: Antonio Palumbo, Jesús F. San Miguel

What is the Role for Monoclonal Antibodies in Multiple Myeloma?

13.20-13.30 **Understanding the Biological Rationale**
Fabio Malavasi

13.30-13.40 **What do the Preclinical Data tell us?**
Sagar Lonial

13.40-13.50 **Panel Discussion**

Current Clinical Experience with anti-CD38 Monoclonal Antibodies:

13.50-14.00 **Single Agent Activity**
Jesús F. San Miguel

14.00-14.10 **Combination Studies**
Antonio Palumbo

14.10-14.30 **Practical Management Consideration for Patients Receiving anti-CD38 Monoclonal Antibodies**
Philippe Moreau

14.30-14.50 **Panel Discussion**

IMMUNOTHERAPY

Chairmen: David E. Avigan, Thierry Facon

14.50-15.10 **SLAMF7 Combinational Monoclonal Antibodies Therapy**
Thierry Facon

15.10-15.30 **CD38, Novel Monoclonal Antibodies Targets, Immunotoxin**
Thomas G. Martin

15.30-15.50 **PDI - PDL1 - Vaccine**
David E. Avigan

15.50-16.10 **CAR-T**
Edward A. Stadtmauer

16.10-16.30 **Bispecific Monoclonal Antibodies**
Jeffrey A. Zonder

SPECIAL CONDITIONS



SANTA CECILIA HALL

Chairmen: Angela Dispenzieri, Jean-Paul Fermand

17.00-17.20 **Monoclonal Gammopathy of Undetermined Significance**

Angela Dispenzieri

17.20-17.40 **Smoldering Multiple Myeloma**

María-Victoria Mateos

17.40-18.00 **Primary Plasma Cell Leukemia**

Niels van de Donk

18.00-18.20 **Amyloid Light-chain Amyloidosis**

Giampaolo Merlini

18.20-18.40 **Waldenström Macroglobulinemia**

Steven P. Treon

POSTER SESSION II

POSTER AREA

18.40-19.40 **Multiple Myeloma Biology, Pathophysiology, Preclinical Studies,**

Bone Disease

Chairman: Noopur Rajee

18.40-19.40 **Multiple Myeloma Therapy in Newly Diagnosed Patients excluding**

Transplantation

Chairman: Heinz Ludwig

18.40-19.40 **Multiple Myeloma Therapy Relapsed/Refractory Patients**

Chairman: Torben Plesner

Saturday, September 26, 2015

MEET THE EXPERTS



Simultaneous sessions in four rooms

07.00-08.00 **Amyloid Light-chain Amyloidosis**

Raymond L. Comenzo, Fortunato Morabito

07.00-08.00 **Waldenström Macroglobulinemia**

Pellegrino Musto, Steven P. Treon

07.00-08.00 **Bone Disease**

Noopur Rajee, Patrizia Tosi

07.00-08.00 **Supportive Care**

Joan Bladé, Maria Teresa Petrucci

DEBATE



SANTA CECILIA HALL

Chairmen: Brian G.M. Durie, Antonio Palumbo

08.00-08.15 **Biomarker to change Therapy Minimal Residual Disease/Imaging**

vs FISH/Age - in Favor of Minimal Residual Disease/Imaging

C. Ola Landgren

08.15-08.30 **Biomarker to change Therapy Minimal Residual Disease/Imaging**

vs FISH/Age - in Favor of FISH/Age

Pieter Sonneveld

08.30-08.45 **Can we cure Multiple Myeloma by 2020? Yes**

Bart Barlogie

08.45-09.00 **Can we cure Multiple Myeloma by 2020? No**

Hartmut Goldschmidt

RISING STARS AWARD



SANTA CECILIA HALL

Chairmen: Brian G.M. Durie, Antonio Palumbo

09.00-09.15 RS-001

Hedgehog Pathway over Expression Identifies Myeloma Patients with worse Prognosis

Marina Martello

TEATRO STUDIO HALL

GREEN ROOM

RED ROOM

BLUE ROOM

YELLOW ROOM

09.15-09.30	RS-002	Preclinical Analysis of Feasibility and Efficacy of CS1 Directed CAR T cell Therapy in Multiple Myeloma in the Autologous Setting Sophia Danhof	11.15-11.30	OP-002	Genome-scale CRISPR-Cas9 Knockout Studies to characterize the Mechanisms of Myeloma Cell Treatment Resistance Yiguo Hu
09.30-09.45	RS-003	Carfilzomib and Dexamethasone in Untreated Symptomatic Multiple Myeloma Peter Forsberg	11.30-11.45	OP-003	Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) (KRd) combined with Autologous Stem Cell Transplant (ASCT) shows Improved Efficacy compared with KRd without ASCT in Newly Diagnosed Multiple Myeloma (NDMM) Andrzej J. Jakubowiak
09.45-10.00	RS-004	Ribosomal dysfunction in AL amyloidosis: Gene Expression Profile Meta-Analysis Fedor Kryukov	11.45-12.00	OP-004	Early Mortality in Elderly Patients with Newly Diagnosed Multiple Myeloma Treated with Novel Agents Alessandra Larocca
BART BARLOGIE YOUNG INVESTIGATOR AWARD 10.00-10.15 Chairmen: Kenneth C. Anderson, Bart Barlogie, Joan Bladé			12.00-12.15	OP-005	Phase I, Multicenter, Open-label, Dose-escalation, Combination Study (NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Dexamethasone (DEX) in Patients with Relapsed and Refractory Multiple Myeloma (MM); Study NPI-0052-107 Preliminary Results Andrew Spencer
10.15-10.30	<i>Coffee break</i>	EXHIBITION AREA			
DEBATE Chairmen: Mario Boccadoro, Hermann Einsele			12.15-12.30	OP-006	The Genomic and Transcriptional Landscape of Waldenström's Macroglobulinemia Impacts Disease Presentation, Overall Survival and Therapeutic Response Zachary Hunter
10.30-10.45	How to incorporate the Newest Agents Combo vs Sequence - in Favor of Combo Faith E. Davies	SANTA CECILIA HALL			
10.45-11.00	How to incorporate the Newest Agents Combo vs Sequence - in Favor of Sequence Shaji K. Kumar	SANTA CECILIA HALL			
PLENARY ABSTRACT SESSION Chairmen: Mario Boccadoro, Hermann Einsele			12.30-13.00	CLOSING CEREMONY	
11.00-11.15	OP-001	A Meta-Analysis Investigating the Impact of Minimal Residual Disease (MRD) Status on Survival Outcomes in Patients with Multiple Myeloma (MM) who Achieve Complete Response (CR) Nikhil Munshi	13.00-14.00	<i>Lunch</i>	



2nd MYELOMA NURSING SYMPOSIUM

Wednesday, September 23, 2015

FACULTY

Annalisa Bernardini
 Beth Faiman
 Tracy King
 Daniela Klarica
 Alessandra Malfitano
 Monica Morris
 Elena Ponticelli
 Tiffany Richards
 Joseph Tariman

10.45-11.00 **Welcome and Open**

Elena Ponticelli, Tracy King

MANAGING TOXICITIES AND SYMPTOMS

TEATRO STUDIO HALL

Chairmen: Daniela Klarica, Tiffany Richards

11.00-11.40 **Keeping Patients on Treatment: Management of Toxicities Related to New Therapies and Challenges of Symptom Management Research**

Beth Faiman

11.40-12.00 **Toxicities Associated with SQ Bortezomib: an Update of the Italian Experience**

Alessandra Malfitano

12.00-12.20 **Evidenced Based Practice for Central Line Care: Impact of New Therapies on Utilization of Venous Access Devices by Patients with Myeloma**

Annalisa Bernardini

12.20-12.40 **The Devils in the Dex: the Experience of High Dose Dexamethasone and Implications for PRO Tool Development**

Tracy King

12.40-13.00 **"We are the Nurses all the Time": the Experience and Supportive Care Needs of the Family in the Era of Novel Myeloma Therapies**

Monica Morris

13.00-14.00 *Lunch*

ABSTRACT SESSION

TEATRO STUDIO HALL

Chairman: Beth Faiman

14.00-14.20 NO-001

Lack of Health Maintenance Exams and Risk: an Internet-Based Survey on Health Maintenance and Preventive Care Patterns in Patients with Myeloma

Joseph D. Tariman

14.20-14.40 NO-002

A CAM do Approach: the attitudes, Use and Disclosure of the Use of Complementary and Alternative Medicine (CAM) in those with myeloma

Tracy King

14.40-15.00 NO-003

A Pilot Placebo Controlled Study to Estimate the Effect Size of Glutamine to Prevent Peripheral Neuropathy in Multiple Myeloma

Beth Faiman

15.00-15.20 NO-004

Development of a Nurse Led Community based Bortezomib Program for Multiple Myeloma (MM)

Daniela Klarica

15.20-15.40 NO-005

Aplasia on the own Couch at Home in Multiple Myeloma Patients after Autologous Stem Cell Transplantation

Iris Agreiter

15.40-16.00 NO-006

Cellular Immunotherapy for Myeloma using Chimeric Antigen Receptor Modified T Cells (CARs)

Patricia Mangan

16.00-16.30 *Coffee break*

NURSING PLENARY

TEATRO STUDIO HALL

Chairman: Monica Morris

16.30-17.15

Integrating Myeloma Genomics into Nursing Practice: Patient Education and Shared Decision Making

Joseph D. Tariman

17.15-17.35

Formation of International Nurses Society

Tracy King

17.35-17.45

IMW 2017 New Delhi Summary and Close

Elena Ponticelli, Tracy King

GENERAL INFORMATION OF THE NURSING SYMPOSIUM

VENUE

Teatro Studio Hall
Auditorium Parco della Musica
Viale de Coubertin, 30
00196 Rome (Italy)
www.auditorium.com

POSTER

Poster session will take place in the Teatro Studio Hall:

Installation

Wednesday, September 23, 2015 9.30 - 10.30 Teatro Studio Hall

Viewing

Wednesday, September 23, 2015 10.30 - 18.00 Teatro Studio Hall

Thursday, September 24, 2015 8.00 - 20.00 Poster Area

Friday, September 25, 2015 8.00 - 20.00 Poster Area

Saturday, September 26, 2015 8.00 - 13.00 Poster Area

Tear off

Saturday, September 26, 2015 13.00 - 14.00 Poster Area

Posters should be installed in Teatro Studio Hall, on the back of the room in order to make posters available during the Nursing Symposium. At the end of the symposium, the Organizing Secretariat staff will move posters in the Poster Area of the meeting.

Materials to hang posters will be available in Teatro Studio Hall. The Congress provides one board for each poster. The author is responsible for hanging and for removing the poster. Please note that the organisers do not take any responsibility for returning uncollected material to the authors. There will be a poster helpdesk where staff will be happy to assist you.

1. Multiple Myeloma Genomics, Diagnosis, Prognosis, Imaging

POSTER DISCUSSION SESSION

Chairman: Nizar J. Bahlis

BP-001	J. Keats	INTERIM ANALYSIS OF THE MMRF COMPASS STUDY: COMPREHENSIVE CHARACTERIZATION OF MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS REVEALS DISTINCT MOLECULAR SUBTYPES AND CLINICAL OUTCOMES
BP-002	M.F. Kaiser	MOLECULAR RISK STRATIFICATION OF 1,036 CASES FROM THE NCRI MYELOMA XI TRIAL USING THE ALL-MOLECULAR DIAGNOSTIC TOOL MYMAP (MYELOMA MLPA AND TRANSLOCATION PCR)
BP-003	R. Kaedbey	NONINVASIVE DIAGNOSIS OF ACTIONABLE MUTATIONS BY DEEP SEQUENCING OF CIRCULATING CELL FREE DNA (CFDNA) IN MULTIPLE MYELOMA (MM)
BP-004	G. Marzocchi	RARE HIGH RISK IGH TRANSLOCATIONS IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM): CYTOGENETIC CHARACTERIZATION AND RELEVANCE ON PROGNOSIS
BP-005	J. Sawyer	JUMPING TRANSLOCATIONS OF 1Q12 IN MULTIPLE MYELOMA: UNEXPECTED INTRA-CLONAL HETEROGENEITY OF COPY NUMBER ABERRATIONS IN THE 1Q21-31 REGION
BP-006	S. Manier	CIRCULATING EXOSOMAL MICRORNAs ARE CRITICAL PROGNOSTIC MARKERS INDEPENDENT OF CYTOGENETICS AND INTERNATIONAL STAGING SYSTEM IN MULTIPLE MYELOMA
BP-008	M. Van Duin	GENE EXPRESSION PROFILE OF MULTIPLE MYELOMA PATIENTS WITH POOR RESPONSE TO BORTEZOMIB INDUCTION THERAPY IN THE HOVON65/GMMG-HD4 STUDY
BP-009	A.C. Rawstron	THE IMPACT OF NORMAL PLASMA CELL RECOVERY ON PROGRESSION-FREE AND OVERALL SURVIVAL IN MYELOMA PATIENTS AFTER ASCT
BP-010	H.E. Johnsen	MULTIPLE MYELOMA SUBTYPING THAT ASSOCIATES NORMAL B-CELL SUBSET PHENOTYPES, DO CORRELATE TO DISEASE STAGE AND PROGNOSIS - INDICATION OF REVERSIBLE PHENOTYPIC PLASTICITY AS A HALLMARK

POSTER SESSION

PO-001	K.M. Kortüm	TARGETED SEQUENCING OF RELAPSED/REFRACTORY MYELOMA PATIENTS IDENTIFIES AN ENRICHMENT OF MUTATIONS IN MAPK AND CEREBLON PATHWAYS	PO-016	J.M. Hernandez	USEFULNESS OF WHOLE-BODY DIFFUSION-WEIGHTED MRI (WB-MRI) WITH APPARENT DIFFUSION COEFFICIENT (ADC) IN THE DIFFERENTIATION OF MONOCLONAL GAMMOPATHIES
PO-002	S. Keppler	(GERMLINE) MUTATIONS IN RECEPTOR TYROSINE KINASES: A PROGNOSTIC MARKER IN MULTIPLE MYELOMA?	PO-017	D.L. Murray	DEVELOPMENT OF A COST-EFFECTIVE CLINICAL ASSAY TO SIMULTANEOUSLY SCREEN, QUANTITATE AND ISOTYPE M-PROTEINS IN REAL-TIME USING MALDI-TOF
PO-003	R. Kuiper	IMPROVED PROGNOSIS IN MULTIPLE MYELOMA BY A SYSTEMATIC COMBINATORIAL APPROACH: COMBINING EMC92 GENE CLASSIFIER WITH ISS RESULTS IN PREDICTION OF HIGH- AND LOW-RISK MULTIPLE MYELOMA	PO-018	A.K. Nooka	SERUM HEAVY LIGHT CHAIN RATIO NORMALIZATION AMONG MULTIPLE MYELOMA PATIENTS ACHIEVING SCR
PO-004	R. De Tute	MINIMAL RESIDUAL DISEASE IN TRANSPLANT INELIGIBLE MYELOMA PATIENTS: RESULTS FROM THE UK NCRI MYELOMA XI TRIAL	PO-019	I. Isola	SMOLDERING MULTIPLE MYELOMA: IMPACT OF THE EVOLVING PATTERN ON EARLY PROGRESSION
PO-006	B. Dalla Palma	RELATIONSHIP BETWEEN PRESENCE OF OSTEOLYTIC LESIONS, CYTOGENETIC FEATURES AND BONE MARROW LEVELS OF CYTOKINES AND CHEMOKINES IN MULTIPLE MYELOMA PATIENTS: ROLE OF CHEMOKINE (C-C MOTIF) LIGAND 20 AS NEW MARKER OF BONE DISEASE	PO-020	J. Straub	EARLY DIAGNOSIS OF MULTIPLE MYELOMA-PROJECT CRAB OF CZECH MYELOMA GROUP(CMG)
PO-007	M. Granell	PROGNOSTIC IMPACT OF CIRCULATING PLASMA CELLS ON SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA	PO-021	A. Silva	A NOVEL APPROACH TO STUDY EVOLUTION OF DRUG RESISTANCE AND OPTIMUM THERAPY IN MULTIPLE MYELOMA
PO-008	H. Caillon	ASSESSMENT OF BIOCHEMICAL RESPONSE FOR MULTIPLE MYELOMA (MM) PATIENTS TREATED WITH DARATUMUMAB: PROPOSAL IN CASSIOPEIA STUDY, IFM 2015/01	PO-022	A. Butrym	POLYMORPHISMS WITHIN IRF4 ENCODING GENE AND ITS SIGNIFICANCE FOR PATIENTS WITH MULTIPLE MYELOMA
PO-009	X. Agirre	WHOLE-EPIGENOME ANALYSIS IN MULTIPLE MYELOMA REVEALS DNA HYPERMETHYLATION OF B CELL-SPECIFIC ENHANCERS	PO-023	P. Milani	A SIMPLE MODEL TO PREDICT SURVIVAL USING AGE, COMORBIDITIES AND FUNCTIONAL STATUS IN PATIENTS WITH MULTIPLE MYELOMA (MM)
PO-010	C. Pawlyn	THE SPECTRUM AND CLINICAL IMPACT OF EPIGENETIC MODIFIER MUTATIONS IN MYELOMA	PO-024	S. McAuliffe	DIGITAL PCR FOR MRD DETECTION OF MYELOMA
PO-011	H.E.H. Møller	MYC PROTEIN EXPRESSION IN MULTIPLE MYELOMA: CLINICOPATHOLOGICAL FEATURES AND PROGNOSTIC IMPACT	PO-025	M. Fujisawa	CLINICAL SIGNIFICANCE OF CIRCULATING PLASMA CELLS IN MYELOMA; 6-COLOR MULTIPARAMETER FLOWCYTOMETRY ANALYSIS
PO-012	P. Boulard	MORNING URINE AS AN ALTERNATIVE TO 24-HOUR URINE ELECTROPHORESIS? RENAL LESIONS ASSESSMENT, MONOCLONAL PEAK DETECTION AND QUANTIFICATION COMPARISONS	PO-026	N. Lee	ANALYSIS OF CD138+ PLASMA CELL PERCENTAGE IN BONE MARROW SECTION USING IMAGE ANALYZER: DISCREPANCIES OF BONE MARROW PLASMA CELL COUNT BETWEEN ASPIRATION AND BIOPSY SECTION IN MULTIPLE MYELOMA
PO-013	S. Ozaki	REVISED INTERNATIONAL STAGING SYSTEM APPLIED TO JAPANESE PATIENTS: A MULTICENTER RETROSPECTIVE COLLABORATIVE STUDY OF THE JAPANESE SOCIETY OF MYELOMA	PO-027	D. Shuhui	CLINICAL ANALYSIS OF MULTIPLE MYELOMA PATIENTS WITH BONE-RELATED EXTRAMEDULLARY DISEASE - A LONGITUDINAL STUDY ON 834 CONSECUTIVE PATIENTS IN A SINGLE CENTER OF CHINA
PO-014	J. Groß	BODY FAT PERCENTAGE AND DISTRIBUTION AS PREDICTIVE FACTORS FOR TREATMENT RESPONSE - A RETROSPECTIVE STUDY IN PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA	PO-028	R. Kumar	EXPLORING THE ROLE OF SHELTERIN COMPLEX AND TELOMERASE ACTIVITY IN MULTIPLE MYELOMA
PO-015	K. Matsue	HEAVY/LIGHT CHAIN ANALYSIS FOR RESPONSE MONITORING IN MULTIPLE MYELOMA PATIENTS: COMPARISONS WITH IMMUNOFIXATION, SERUM FREE LIGHT CHAIN, AND MULTICOLOR FLOW-CYTOMETRY ANALYSIS	PO-029	P. Yadav	PRESENTATION FREE LIGHT CHAIN LEVELS AND AGE ARE THE STRONGEST PREDICTORS OF RENAL FUNCTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
			PO-030	E.K. Mai	ASSOCIATION BETWEEN MAGNETIC RESONANCE IMAGING PATTERNS AND BASELINE DISEASE FEATURES IN MULTIPLE MYELOMA: ANALYZING SURROGATES OF TUMOR MASS AND BIOLOGY

PO-031	H. Takamatsu	COMPARISON OF MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA BETWEEN MULTIPARAMETER FLOW CYTOMETRY AND DEEP-SEQUENCING	PO-044	Y.K. Lee	CYTOGENETIC ABNORMALITIES OF UNDETERMINED CLINICAL SIGNIFICANCE CORRELATE WITH POOR PROGNOSIS: FACTORS IN MULTIPLE MYELOMA
PO-032	J. de la Rubia	GAH SCALE IS A SIMPLE, COMPREHENSIVE ASSESSMENT TOOL IN OLDER PATIENTS WITH HEMATOLOGICAL MALIGNANCIES THAT SHOWS MORTALITY PREDICTION CAPACITIES	PO-045	D. Ryu	WHOLE-EXOME SEQUENCING AND TRANSCRIPTOME ANALYSIS FOR IGM MULTIPLE MYELOMA
PO-033	R. Jiménez	OUTCOME OF PATIENTS WITH EXTRAMEDULLARY PLASMACYTOMAS (EMPS) INCLUDED IN A PHASE III PETHEMAGEM STUDY OF INDUCTION THERAPY PRIOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MULTIPLE MYELOMA (MM)	PO-046	S. Savary Bélangier	EARLY EVALUATION OF RESPONSE BY SERUM FREE LIGHT CHAIN (FLC) AND HEVYLITE (HLC) IN INTACT IMMUNOGLOBULIN (IIG) MULTIPLE MYELOMA (MM): PREDICTION OF OUTCOME
PO-034	P. Pusciznova	RELATIONSHIP OF SERUM LEVELS OF SELECTED BIOLOGICAL INDICATORS AND CYTOGENETIC ABNORMALITIES IN MULTIPLE MYELOMA	PO-047	G. Graziani	ASSESSMENT OF TIME FROM ONSET OF FIRST SYMPTOMS TO THE FINAL DIAGNOSIS OF MULTIPLE MYELOMA (MM) - POSSIBLE RISKS AND FUTURE SOLUTIONS
PO-035	J. Krönke	INFLUENCE OF CRBN, IKZF1, AND IKZF3 EXPRESSION ON OUTCOME IN LENALIDOMIDE TREATED NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS	PO-048	S. Pans	ASSESSING PROGRESSIVE DISEASE IN MYELOMA PATIENTS WITH WHOLE-BODY DIFFUSION-WEIGHTED IMAGING AT 3.0 T: A PROSPECTIVE IMAGING STUDY COMPARING WHOLE BODY T1-WI, T2-STIR-WI AND LABORATORY FINDINGS
PO-036	M. Andrade Campos	RESPONSE AND EARLY RELAPSE ASSESSMENT IN MULTIPLE MYELOMA TREATED WITH BORTEZOMIB: ROLE OF HEAVY/LIGHT-CHAIN IMMUNEASSAY	PO-049	M. Andrade Campos	MYELOMA MULTIPLE (MM) IGA SUBTYPE: USEFULNESS OF HEAVY/LIGHT IGAK/IGAL QUANTIFICATION FOR DIAGNOSIS AND FOLLOW-UP
PO-037	M. Itagaki	RISK FACTORS OF DEVELOPING SYMPTOMATIC MYELOMA FROM MGUS: ANALYSIS IN OUR HOSPITAL	PO-050	W. Willenbacher	LOW BECLIN-1 EXPRESSION PREDICTS IMPROVED OVERALL SURVIVAL IN PATIENTS TREATED WITH IMMUNE-MODULATORY DRUGS FOR MULTIPLE MYELOMA AND IDENTIFIES AUTOPHAGY INHIBITION AS A PROMISING POTENTIALLY DRUGGABLE NEW THERAPEUTIC TARGET. AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY (AMR)
PO-038	G. Barilà	DIFFUSION WEIGHTED WHOLE BODY MRI FOR EARLY EVALUATION OF RESPONSE IN MULTIPLE MYELOMA	PO-051	S. Gentili	NORMALIZATION OF SERUM FREE LIGHT CHAIN RATIO AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA AS A MAJOR CRITERIA RESPONSE
PO-039	S. Pans	MYELOMA BONE LESIONS ON WHOLE-BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING AT 3.0 T: CHARACTERIZATION AND COMPARISON OF APPARENT DIFFUSION COEFFICIENT AND B1000 VALUE ON 2 DIFFERENT MRI PLATFORMS OF THE SAME VENDOR	PO-052	P.J. Talley	RESULTS FROM FIRST PILOT CEGAS FOR MYELOMA GENETIC DIAGNOSIS
PO-040	P. Yadav	RENAL FUNCTION AND AGE AT PRESENTATION AND SERUM FREE LIGHT CHAIN RESPONSE AT POST-INDUCTION PREDICT RENAL OUTCOME	PO-053	A. Kennard	COMPARISON OF FREE LIGHT AND N LATEX SERUM FREE LIGHT CHAIN ASSAYS IN SUBJECTS WITH END STAGE RENAL DISEASE ON HAEMODIALYSIS
PO-041	L. Soares Vieira Da Silva	PREVALENCE OF OLIGOCLONAL BANDS IN MULTIPLE MYELOMA PATIENTS WHO ACHIEVED AT LEAST VERY GOOD PARTIAL RESPONSE AFTER TREATMENT WITH STANDARD OR HIGH DOSE CHEMOTHERAPY- FINAL ANALYSIS	PO-054	S. Hwang	CLONAL CHANGES ARE FREQUENTLY DETECTED BY CYTOTOPLASMIC IMMUNOGLOBULIN-FLUORESCENCE IN SITU HYBRIDIZATION WITH PROGRESSION OF MULTIPLE MYELOMA
PO-042	M. Andrade Campos	DETECTING EARLY RELAPSE IN MULTIPLE MYELOMA (MM) AFTER ASCT: USEFULNESS OF IMMUNEASSAYS	PO-055	J.J. Lee	PROGNOSTIC VALUE OF THE INVERSE PLATELET-TO-LYMPHOCYTE RATIO (IPLR) IN PATIENTS WITH MULTIPLE MYELOMA WHO WERE TREATED UPFRONT WITH A NOVEL-AGENT-CONTAINING REGIMEN
PO-043	C. Surtiu	ABSOLUTE LYMPHOCYTE COUNT AS A PROGNOSTIC MARKER IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED IN THE ERA OF NOVEL AGENTS	PO-056	J.J. Lee	EARLY MORTALITY IN THE PATIENTS WITH MULTIPLE MYELOMA WHO WERE TREATED UPFRONT WITH A NOVEL AGENT-CONTAINING REGIMEN

PO-057	J. Batini	UTILITY OF THE HEAVY/LIGHT CHAIN ASSAY IN THE EVALUATION OF COMPLETE RESPONSE TO THERAPY IN MULTIPLE MYELOMA PATIENTS	PO-073	P.P. Kotoucek	CAPILLARY ZONE ELECTROPHORESIS IS A VERY SENSITIVE METHOD FOR DIAGNOSIS AND MONITORING OF MULTIPLE CLONES OF MULTIPLE MYELOMA, OTHER PLASMA CELL DYSCRASIAS AND LYMPHOPROLIFERATIVE DISORDERS
PO-058	N. Nishimura	MULTIPLE MYELOMA AS A SECOND PRIMARY MALIGNANCY; ONE FOURTH OF PATIENTS HAD PRIOR HISTORY OF OTHER MALIGNANCIES	PO-074	A. Zober	PROSPECTIVE ASSESSMENT OF A COMORBIDITY AND FUNCTIONAL GERIATRIC ASSESSMENT (CF-GA), INCLUDING THE REVISED FREIBURG COMORBIDITY INDEX (RFCI) IN MM PATIENTS (PTS)
PO-059	M. Cook	THE IMPACT OF DIALYSIS-DEPENDENT ACUTE KIDNEY INJURY ON MORTALITY IN MYELOMA: FINDINGS FROM ENGLAND HOSPITAL EPISODE STATISTICS DATA	PO-075	D.S. Kim	NOVEL PROGNOSTIC MODEL OF COMBINATION NEUTROPHIL-LYMPHOCYTE RATIO, PLATELET COUNT, AND C-REACTIVE PROTEIN MIGHT PREDICT PROGNOSIS OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
PO-060	W.K. Jeong	EXPIRATION: INSPIRATION RATIO AS A PROGNOSTIC FACTOR IN SYSTEMIC ALAMYLOIDOSIS	PO-076	Y. Meddour	PROGNOSTIC VALUE OF FLOW CYTOMETRIC ANTIGEN EXPRESSION PATTERN ON BONE MARROW NEOPLASTIC PLASMA CELLS FROM MULTIPLE MYELOMA PATIENTS
PO-061	E. Lee	BASELINE F-18 FDG PET UPTAKE OF BONE MARROW AS A SURVIVAL PREDICTOR IN PATIENTS WITH MULTIPLE MYELOMA	PO-077	T. Pika	TRANSLOCATION T(8;14) IN MULTIPLE MYELOMA DEFINES PATIENTS WITH VERY POOR PROGNOSIS – SINGLE CENTRE EXPERIENCE
PO-062	R. Bergner	INFLUENCE OF KIDNEY HISTOLOGY ON PROGNOSIS IN MULTIPLE MYELOMA	PO-078	S. Cerdá	IMWG '03 VS '14 DIAGNOSTIC CRITERIA FOR SYMPTOMATIC MULTIPLE MYELOMA: WILL WE HAVE TO SOLVE A PROBLEM?
PO-063	M. Ikeda	THE CLINICAL SIGNIFICANCE OF DECREASING CD138 POSITIVE MYELOMA CELLS IN BONE MARROW	PO-079	Y. Meddour	CLINICAL VALUE OF SERUM FREE LIGHT CHAIN ASSAY IN ALGERIAN NEWLY DIAGNOSED MULTIPLE MYELOMA UNDERGOING HIGH DOSE THERAPY
PO-064	I. Walker	A SINGLE CENTRE RETROSPECTIVE ANALYSIS OF DIAGNOSTIC FLUORESCENCE IN SITU HYBRIDISATION REVEALS DISTINCT GROUPS OF CYTOGENETIC ABNORMALITIES, WHICH AFFECT EARLY SURVIVAL OF NEW MYELOMA DIAGNOSIS	PO-080	A. Ghosh	A CYTOF-BASED APPROACH TO DETECT MINIMAL RESIDUAL DISEASE IN PATIENTS WITH MULTIPLE MYELOMA
PO-065	S.S. Yoon	REVEALING GENOMIC PROFILE THAT UNDERLIES TROPISM OF MYELOMA CELLS USING WHOLE EXOME SEQUENCING	PO-081	N. Schütz	FRAILTY BURDEN IS ASSOCIATED WITH SURVIVAL IN ELDERLY PATIENTS WITH DIAGNOSIS OF MULTIPLE MYELOMA
PO-066	J. Dallemagne	COMPARISON OF BONE MARROW ASPIRATE AND BONE MARROW BIOPSY IN THE WORKUP OF PATIENTS WITH MULTIPLE MYELOMA	PO-082	J.A. Kim	MYD88 L265P MUTATIONS ARE CORRELATED WITH 6Q DELETION IN KOREAN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
PO-067	T.A. Richards	CHARACTERISTICS OF MYELOMA (MM) PATIENTS (PTS) WITH CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT	PO-083	O. Annibaldi	ALKALINE PHOSPHATASE (ALP) LEVELS IN MULTIPLE MYELOMA (MM) AND CANCER WITH BONE LESIONS: IS THERE ANY DIFFERENCE?
PO-068	S. Hagiwara	HIGH EXPRESSION OF AF1Q1 IS AN ADVERSE PROGNOSTIC FACTOR IN MULTIPLE MYELOMA PATIENTS TREATED WITH AUTOLOGOUS STEM CELL TRANSPLANTATION	PO-084	A. Jorge	CENTRAL NERVOUS SYSTEM INFILTRATION BY PLASMA CELLS: RARE OCCURRENCE IN MULTIPLE MYELOMA PATIENTS
PO-069	H. Zhou	EXPRESSION OF MTH1 IN MULTIPLE MYELOMA AND ITS RELATIONSHIP WITH THERAPEUTIC RESPONSE	PO-085	M. Zarrouk	PROGNOSTIC IMPLICATION OF CYTOGENETIC ABNORMALITIES FOR NEWLY DIAGNOSED MULTIPLE MYELOMA IN YOUNG PATIENTS: TUNISIAN MONOCENTER EXPERIENCE
PO-070	I. Jaffer Sathick	CYST NEPHROPATHY VS ACUTE TUBULAR NECROSIS IN NEWLY DIAGNOSED MULTIPLE MYELOMA: A COMPARATIVE STUDY	PO-086	D. Stoumbos	HIGH SERUM LACTATE DEHYDROGENASE LEVEL USED AS A PROGNOSTIC FACTOR IN MULTIPLE MYELOMA
PO-071	H. Plonkova	COMPARISON OF WHOLE-BODY LOW-DOSE COMPUTED TOMOGRAPHY AND CONVENTIONAL RADIOGRAPHY IN THE STAGING OF MULTIPLE MYELOMA			
PO-072	V. Maisnar	THE SIGNIFICANCE OF HEVYLITE TEST FOR DETERMINATION OF PROGNOSIS IN PATIENTS WITH ASYMPTOMATIC MULTIPLE MYELOMA: THE RESULTS OF A NEW CLINICAL PROSPECTIVE			

2. Multiple Myeloma Therapy in Newly Diagnosed Patients including Transplantation

POSTER DISCUSSION SESSION

Chairman: Andrzej J. Jakubowiak

BP-011 L. Rosiñol

PRETRANSPLANT INDUCTION WITH VTD (BORTEZOMIB/THALIDOMIDE /DEXAMETHASONE) SIGNIFICANTLY IMPROVES PFS: LONG-TERM RESULTS OF THE RANDOMIZED PHASE 3 PETHEMA/GEM STUDY

BP-012 C. Pawlyn

THE QUADRUPLET KCRD (CARFILZOMIB, CYCLOPHOSPHAMIDE, LENALIDOMIDE, AND DEXAMETHASONE) IS SAFE AND WELL TOLERATED AS INDUCTION THERAPY FOR NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE, MYELOMA PATIENTS

BP-013 P. Hari

INDUCTION REGIMENS FOR AUTOLOGOUS TRANSPLANT (AHCT) ELIGIBLE MYELOMA (MM) PATIENTS (PTS) – DOUBLET'S OR TRIPLET'S AND WHICH TRIPLET?

BP-014 D. Reece

MYELOMA CANADA RESEARCH NETWORK (MCRN) 001 TRIAL WITH INTRAVENOUS (IV) BUSULFAN + MELPHALAN (BUMEL) AS ENHANCED CONDITIONING, FOLLOWED BY LENALIDOMIDE (LEN) MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS (PTS): FIRST RESULTS OF MINIMAL RESIDUAL DISEASE (MRD) AND HEVYLITE(TM) CHAIN (HLC) ASSAYS AT DAY 100 POST AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)

BP-015 A. Kalfif

IMMUNOHISTOCHEMICAL (IHC) BIOMARKERS ASSOCIATED WITH RESPONSE AND SURVIVAL FOLLOWING LENALIDOMIDE AND PREDNISOLONE MAINTENANCE POST-ASCT IN PATIENTS WITH MM: AN EXPLORATORY, HYPOTHESIS GENERATING SUB-STUDY OF THE LEOPARD TRIAL

BP-016 R. Mina

IMPACT OF COMPLETE RESPONSE ON PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN NEWLY DIAGNOSED MYELOMA PATIENTS TREATED WITH AUTOLOGOUS STEM CELL TRANSPLANTATION OR CONVENTIONAL CHEMOTHERAPY: RESULTS OF A POOLED ANALYSIS OF 5 PHASE III TRIALS

BP-017 C. Cerrato

CONTINUOUS TREATMENT IMPROVES SURVIVAL OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ACHIEVING COMPLETE RESPONSE: DATA FROM 5 PHASE III TRIALS INCLUDING YOUNG AND ELDERLY PATIENTS

BP-018 K. Weisel

THE TREATMENT (TX) OF PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) INELIGIBLE FOR TRANSPLANT: A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

BP-019 X. Qin

MULTIPLE MYELOMA PATIENTS WITH UNMEASURABLE DISEASE BENEFIT LESS FROM BORTEZOMIB-BASED REGIMENS

BP-020 N. Bahls

IMPACT OF RESPONSE IN PATIENTS (PTS) WITH STEM CELL TRANSPLANT (SCT)-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TREATED WITH CONTINUOUS LENALIDOMIDE + LOW DOSE DEXAMETHASONE (LD) IN THE FIRST TRIAL

POSTER SESSION

PO-087 M. Mohty

FRONTLINE THERAPY FOR MULTIPLE MYELOMA (MM) IN REAL-WORLD CLINICAL PRACTICE: RESULTS FROM THE THIRD INTERIM ANALYSIS OF THE MULTINATIONAL, NON-INTERVENTIONAL, OBSERVATIONAL EMMOS STUDY

PO-088 A. Jurczyszyn

CENTRAL NERVOUS SYSTEM INVOLVEMENT BY MULTIPLE MYELOMA: A MULTI-INSTITUTIONAL RETROSPECTIVE STUDY OF 172 PATIENTS

PO-089 O. Sezer

IMPROVED TUMOR RESPONSE AND SURVIVAL OUTCOMES WITH POST-TRANSPLANT BORTEZOMIB (BTZ) CONSOLIDATION VERSUS OBSERVATION (OBS) ALONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM): RESULTS FROM A RANDOMIZED, OPEN-LABEL, MULTICENTER, PARALLEL-GROUP PHASE 2 STUDY

PO-090 C. Hulin

CONTINUOUS TREATMENT WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE FOR PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE FIRST TRIAL: IMPACT OF AGE

PO-091 A. Natale

IMPROVEMENT OF QUALITY OF RESPONSE AFTER ADDITIONAL THERAPY BEFORE AUTOLOGOUS STEM CELL TRANSPLANT IS NOT TRANSLATED IN IMPROVEMENT OF GLOBAL OUTCOME OF MULTIPLE MYELOMA PATIENTS

PO-092 P. Lawasut

EFFECT OF HIGH DOSE MELPHALAN ADMINISTRATION SCHEDULE: COMPARISON BETWEEN 1-DAY AND 2-DAY DOSE FOR MYELOMA CONDITIONING REGIMEN

PO-093 A. Kalfif

A 2-STAGE PHASE II STUDY OF PANOBINOSTAT CONSOLIDATION IN MYELOMA PATIENTS WITH < CR FOLLOWING HIGH-DOSE CHEMOTHERAPY (HDT) CONDITIONED AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)

PO-094 A. Kalfif

LEOPARD: A PHASE II STUDY OF POST AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) MAINTENANCE LENALIDOMIDE AND PREDNISOLONE FOR MYELOMA (MM), INCORPORATING MINIMAL RESIDUAL DISEASE (MRD) ASSESSMENTS

PO-095 I. Ahmad

FAVORABLE LONG-TERM SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA USING A FRONTLINE TANDEM APPROACH WITH AUTOLOGOUS AND NONMYELOABLATIVE ALLOGENEIC TRANSPLANTATION

PO-096 T. Facon

UPDATED OVERALL SURVIVAL (OS) ANALYSIS OF THE FIRST STUDY: LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD) CONTINUOUS VS MELPHALAN, PREDNISONE, AND THALIDOMIDE (MPT) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

PO-097 H. Ludwig

HEAVY/LIGHT CHAIN ASSAYS IDENTIFY MONOCLONAL INTACT IMMUNOGLOBULIN IN 'LIGHT CHAIN ONLY' PATIENTS

PO-098	A. Gozzetti	BORTEZOMIB BASED THERAPIES AND HIGH CUT OFF FILTER DIALYSIS (HCO) ARE EFFECTIVE IN MULTIPLE MYELOMA PATIENTS WITH END STAGE RENAL FAILURE	PO-110	G. Somlo	TOTAL MARROW IRRADIATION (TMI) WITH HELICAL TOMOTHERAPY AND PERIPHERAL BLOOD PROGENITOR CELL RESCUE (PBPC) FOLLOWING HIGH-DOSE MELPHALAN (MEL) AND PBPC AS PART OF TANDEM AUTOLOGOUS TRANSPLANT (TAT) FOR PATIENTS WITH MULTIPLE MYELOMA
PO-099	F. De Arriba	SUBCUTANEOUS BORTEZOMIB PLUS MELPHALAN AND PREDNISONE (VMP) IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS: SPANISH EXPERIENCE	PO-111	J.R. Eveillard	APPRAISAL OF IGM KAPPA/IGM LAMBDA VARIATIONS USING HEVYLITE® AFTER RITUXIMAB AS CONSOLIDATION THERAPY IN PATIENTS WITH WALDENSTRÖM'S MACROGLOBULINEMIA
PO-100	T. Dejoie	SERUM FREE LIGHT CHAIN CHANGES OFFER A MORE ACCURATE ASSESSMENT OF RESPONSE TO THERAPY THAN URINE BENCE JONES PROTEIN EXCRETION MEASUREMENTS IN MULTIPLE MYELOMA	PO-112	K.T. Andersen	SAFETY AND EFFICACY OF FIRST-LINE TREATMENT WITH DOXORUBICIN, CYCLOPHOSPHAMIDE, BORTEZOMIB, DEXAMETHASONE AND LENALIDOMIDE (ACVDL) IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS OF ALL AGES
PO-101	S. Grammatico	EFFICACY OF NEW DRUGS AS TREATMENT BEFORE SINGLE OR TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS	PO-113	V. Kukreti	OUTCOME OF T(4;14) IN MULTIPLE MYELOMA – PRINCESS MARGARET CANCER CENTRE EXPERIENCE OVER THE LAST 10 YEARS
PO-102	J.J. Shah	CLINICAL OUTCOMES IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) AND T(4;14) IN THE CONNECT MM® REGISTRY	PO-114	L. Kumar	AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR MULTIPLE MYELOMA (MM): PREDICTORS OF LONG TERM OUTCOME
PO-103	R. Silvennoinen	A RANDOMIZED PHASE II STUDY OF STEM CELL MOBILIZATION WITH CYCLOPHOSPHAMIDE + G-CSF VERSUS G-CSF ALONE AFTER LENALIDOMIDE-BASED INDUCTION IN MULTIPLE MYELOMA	PO-115	L. Kumar	LOW DOSE DEXAMETHASONE PLUS LENALIDOMIDE (LEN-DEXA) VERSUS THALIDOMIDE (THAL-DEXA) AS INDUCTION THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: A PHASE III, RANDOMIZED STUDY
PO-104	N. Areethamsirikul	LONG TERM CRYOPRESERVED AUTOLOGOUS BLOOD STEM CELLS FOR SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELAPSED MULTIPLE MYELOMA (MM) PATIENTS	PO-116	B. Gamberi	LENALIDOMIDE MAINTENANCE CAUSES PERSISTENCE OF ABNORMAL PROTEIN BANDS IN MULTIPLE MYELOMA PATIENTS AFTER INDUCTION WITH NEW DRUGS AND AUTOLOGOUS BONE MARROW TRANSPLANTATION
PO-105	M. Dimopoulos	CONTINUOUS LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND RENAL IMPAIRMENT IN THE FIRST TRIAL	PO-117	S. Cerdá	AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) OVER 65 YEARS
PO-106	N. Lendvai	RECOMBINANT MAGE-A3 PROTEIN IMMUNOTHERAPY AND PERIPHERAL BLOOD LYMPHOCYTE (PBL) RECONSTITUTION INDUCE STRONG ANTIGEN-SPECIFIC HUMORAL AND CELLULAR IMMUNE RESPONSES IN PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR CONSOLIDATION OF MULTIPLE MYELOMA (MM)	PO-118	A. Roque	EARLY CLINICAL OUTCOMES AND LONG-TERM SURVIVAL IN MM PATIENTS UNDERGOING AUTOLOGOUS HSCT AFTER MELPHALAN 200 MG/M2 CONDITIONING WITHOUT WEIGHT-BASED DOSE-ADJUSTMENT ARE UNAFFECTED BY BODY MASS INDEX
PO-107	J. Shin	LONG-TERM EFFICACY OF SEQUENTIAL VINCRISTINE, ADRIAMYCIN, AND DEXAMETHASONE (VAD) AND BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE (VTD) AS INDUCTION CHEMOTHERAPY FOLLOWED BY HIGH-DOSE MELPHALAN WITH AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTO-SCT) AND BORTEZOMIB CONSOLIDATION: A FOLLOW-UP STUDY OF KMM51	PO-119	V.H. Jimenez Zepeda	PROGNOSTIC FACTORS FOR OVERALL AND PROGRESSION-FREE SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING SINGLE AUTO-SCT
PO-108	C. Lalayanni	IMPACT OF ANTI-MYELOMA INDUCTION TREATMENT AND OTHER PREDICTIVE FACTORS ON STEM CELL HARVESTING, IN THE NOVEL-AGENT ERA	PO-120	M. Merz	OUTCOME AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MYELOMA IN PATIENTS BEYOND 60, 65 AND 70 YEARS OF AGE: A RETROSPECTIVE ANALYSIS FROM THE GERMAN REGISTRY FOR STEM CELL TRANSPLANTATION (DRST)
PO-109	V.H. Jimenez Zepeda	CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBOR) INDUCTION: IMPACT ON RESPONSE RATE AND MDR NEGATIVITY FOR PATIENTS WITH MULTIPLE MYELOMA UNDERGOING	PO-121	C.C. Chua	A MULTI-CENTRE REVIEW OF MOBILISATION STRATEGIES POST UPFRONT VCD INDUCTION IN MULTIPLE MYELOMA: IS G-CSF ALONE SUFFICIENT?

PO-122	A. Jurczyszyn	SKIN INVOLVEMENT BY MULTIPLE MYELOMA: A MULTI-INSTITUTIONAL RETROSPECTIVE STUDY OF 53 PATIENTS	PO-136	S.K. Park	THE TREATMENT STRATEGIES IN PATIENTS WITH PARTIAL RESPONSE TO HIGH-DOSE CHEMOTHERAPY AND ASCT
PO-123	G.L. Shah	A RESPONSE ADAPTED APPROACH TO INDUCTION TREATMENT YIELDS ACCEPTABLE OUTCOME IN PATIENTS WITH MULTIPLE MYELOMA (MM) UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)	PO-137	R. Pramanik	ENGRAFTMENT SYNDROME DURING AUTO HSCT IN PLASMA CELL DISORDERS: RETROSPECTIVE ANALYSIS OF CONSECUTIVE CASES FROM A TERTIARY CARE CENTRE
PO-124	P. Lawasut	VCD, VD AND VMP IN FRONT LINE TREATMENT: OUTCOMES FROM THAI MYELOMA WORKING GROUP – PATIENT ASSISTANCE PROGRAM (TMWG-PAP)	PO-138	L. Floro	RETROSPECTIVE ANALYSIS OF THE IMPACT OF KIDNEY FUNCTION ON THE OUTCOMES OF FIRST AUTOGRAFTS FOR DE NOVO MYELOMA PATIENTS IN THE ERA OF NOVEL AGENTS
PO-125	E. de Queiroz Crusoe	NUMBER OF CD34+ CELLS COLLECTED BETWEEN TWO DIFFERENT MOBILIZATION SCHEDULES IN MULTIPLE MYELOMA PATIENTS WITH CTD INDUCTION AND CANDIDATES FOR AUTOLOGOUS TRANSPLANT OF HEMATOPOIETIC PROGENITOR CELLS	PO-139	O. Berlanga	COMPARISON OF THE PERFORMANCE OF THE NEWLY DEVELOPED IGG HEAVY CHAIN/LIGHT CHAIN IMMUNOASSAYS WITH SERUM PROTEIN ELECTROPHORESIS FOR MONITORING IGG MULTIPLE MYELOMA PATIENTS
PO-126	J. Sangha	PROGRESSION-FREE SURVIVAL FOLLOWING AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE MYELOMA IS NOT COMPROMISED BY THE USE OF DOSE-ADJUSTED MELPHALAN	PO-140	V.H. Jimenez Zepeda	IDENTIFICATION OF PREDICTOR FACTORS FOR EARLY RELAPSE (ER) IN PATIENTS WITH MM UNDERGOING SINGLE AUTO-SCT
PO-127	E.S. Van Laar	SUCCESSFUL ASSESSMENT AND EDUCATIONAL INTERVENTION OF GUIDELINE-BASED APPROACHES FOR THE MANAGEMENT OF MULTIPLE MYELOMA	PO-141	T. Chou	PHASE 1 STUDY OF ELOTUZUMAB (ELO) IN COMBINATION WITH LENALIDOMIDE/DEXAMETHASONE (LENDEX) IN JAPANESE PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) AND LONG-TERM FOLLOW-UP
PO-128	N. Takezako	THE EFFICACY AND SAFETY OF HIGH DOSE MELPHARAN PLUS BORTEZOMIB FOLLOWED BY AUTO PBSCT IN ELDERLY MULTIPLE MYELOMA PATIENTS	PO-142	Y. Xu	SUBCUTANEOUS ADMINISTRATION OF BORTEZOMIB SIGNIFICANTLY DECREASED AND DELAYED THE DEVELOPMENT OF PERIPHERAL NEUROPATHY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
PO-129	O. Berlanga	COMPARISON OF THE PERFORMANCE OF THE NEWLY DEVELOPED IGA HEAVY CHAIN/LIGHT CHAIN IMMUNOASSAYS WITH SERUM PROTEIN ELECTROPHORESIS AND NEPHELOMETRIC TOTAL IGA MEASUREMENTS FOR MONITORING IGA MULTIPLE MYELOMA PATIENTS	PO-143	C. Attwood	MELPHALAN 140MG/M ² SIGNIFICANTLY REDUCES 5 YEAR PROGRESSION FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTS RECEIVING A PERIPHERAL BLOOD AUTOLOGOUS STEM CELL TRANSPLANT COMPARED WITH MELPHALAN 200MG/M ²
PO-130	O.S. Yeu	PRE TRANSPLANT ACHIEVEMENT OF VERY GOOD PARTIAL RESPONSE RESULTS IN IMPROVED SURVIVAL IN MYELOMA	PO-144	L. Floro	REGISTRY BASED RETROSPECTIVE ANALYSIS OF BENDAMUSTINE CONDITIONED SECOND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTS FOR RELAPSED MYELOMA
PO-131	S.H. Lim	EARLY PROGRESSION (WITHIN 12 MONTHS) AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA	PO-145	I. Hardan	THE EMPEROR IS NAKED: THE QUALITY OF RESPONSE TO FIRST-LINE THERAPY IS NOT RELATED TO SURVIVAL IN MULTIPLE MYELOMA (MM) PATIENTS
PO-132	H. Ryu	CLINICAL FEATURES AND OUTCOMES AFTER AUTO-SCT IN PATIENTS WITH MULTIPLE MYELOMA AND RENAL IMPAIRMENT	PO-146	J.J. Lee	PHASE 2 STUDY USING INTRAVENOUS BUSULFAN AND MELPHALAN CONDITIONING REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: INTERIM ANALYSIS (KMM150)
PO-133	W. Poenisch	STEM CELL MOBILIZATION AND AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER PRETREATMENT CONSISTING OF BENDAMUSTINE, PREDNISONE AND BORTEZOMIB (BPV) IN 35 PATIENTS WITH NEWLY DIAGNOSED/UNTREATED MULTIPLE MYELOMA	PO-147	S. Ahmed	INCREASED INCIDENCE OF SYMPTOMATIC POSTURAL HYPOTENSION IN MULTIPLE MYELOMA PATIENTS TREATED WITH SUBCUTANEOUS BORTEZOMIB
PO-134	V. Hungria	SERUM FREE LIGHT CHAIN ASSAYS; NOT TOTAL LIGHT CHAIN ASSAYS, ARE THE STANDARD OF CARE IN THE ASSESSMENT OF MONOCLONAL GAMMOPATHIES	PO-148	K. Weisel	HEALTH RESOURCE UTILIZATION WITH CONTINUOUS LENALIDOMIDE TREATMENT (TX) IN ELDERLY PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

3. Epidemiology, QoL, Toxicities, and Other Plasma Cell Dyscrasias

POSTER DISCUSSION SESSION

Chairman: Raymond L. Comenzo

PO-149	C. Cecchini	SUCCESSFUL STEM CELL COLLECTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS OVER 65 YEARS OLD
PO-150	J. Radocha	AUTOLOGOUS STEM CELL COLLECTION AFTER BIOSIMILAR G-CSF (ZARZIO®) COMPARED TO ORIGINAL G-CSF (NEUPOGEN®) IN MULTIPLE MYELOMA PATIENTS
PO-151	H. Mrachacz	SUCCESSFUL TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED/UNTREATED LIGHT CHAIN MULTIPLE MYELOMA WITH A COMBINATION OF BENDAMUSTINE; PREDNISONE AND BORTEZOMIB (BPV)
PO-152	T. Dejoie	COMPARISON OF THE CLINICAL SENSITIVITY OF TWO FREE LIGHT CHAIN ASSAYS IN A COHORT OF LIGHT CHAIN MULTIPLE MYELOMA PATIENTS
PO-153	R. Garcia Sanchez	FRONTLINE TREATMENT SCHEME VTD (BORTEZOMIB/ THALIDOMIDE/DEXAMETHASONE) IN PATIENTS WITH MULTIPLE MYELOMA TRANSPLANT CANDIDATES AT OUR CENTER
PO-154	H.N. Song	AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AL AMYLOIDOSIS
PO-155	E. Kaul	DAY 4 PERIPHERAL BLOOD STEM CELL COLLECTION IN MYELOMA PATIENTS IS FEASIBLE AND COST-EFFECTIVE IN A MAJORITY OF PATIENTS
PO-156	J.R. Eveillard	EVALUATION OF THE NOVEL HEVYLITE® IGM KAPPA/IGM LAMBDA ASSAYS IN WALDENSTROM'S MACROGLOBULINEMIA PATIENTS AFTER RITUXIMAB CONSOLIDATION THERAPY
PO-157	R. Rios-Tamayo	THE EVOLVING ROLE OF STEM CELL TRANSPLANT IN MULTIPLE MYELOMA: A SINGLE INSTITUTION STUDY
PO-158	R.R. Boya	PREDICTION OF POOR MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS (PBSC) WITH G-CSF ALONE, IN MULTIPLE MYELOMA (MM) PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANTATION: A PROSPECTIVE STUDY
PO-159	Z. Bolaman	STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE
PO-160	M. Quaresima	BORTEZOMIB BASED REGIMEN IN YOUNG HIGH RISK MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: TWO CLINICAL CASES
PO-161	S.K. Toprak	AUTOLOGOUS STEM CELL TRANSPLANTATION AND PRIMARY SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS
PO-162	J. San Miguel	FOUR PHASE 3 STUDIES OF THE ORAL PROTEASOME INHIBITOR (PI) IXAZOMIB FOR MULTIPLE MYELOMA IN THE NEWLY-DIAGNOSED, RELAPSED/REFRACTORY, AND MAINTENANCE SETTINGS: TOURMALINE-MM1, -MM2, -MM3, AND -MM4
PO-163	C.C. Hofmeister	CENTAURUS (JNJ54674141SMM2001): A RANDOMIZED PHASE II TRIAL TO EVALUATE THE EFFECTS OF CARVATAMAB, A CD38-SPECIFIC ANTIBODY, IN COMBINATION WITH BLENTOBIOMES, A CD138-SPECIFIC ANTIBODY, IN MULTIPLE MYELOMA PATIENTS WITH AL AMYLOIDOSIS
BP-021	A. Jaccard	A PROSPECTIVE PHASE II TRIAL OF LENALIDOMIDE AND DEXAMETHASONE (LEN-DEX) IN POEMS SYNDROME
BP-022	G. Cook	AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH POEMS SYNDROME RESULTS IN DURABLE SYMPTOMATIC DISEASE CONTROL: A RETROSPECTIVE STUDY OF THE PLASMA CELL DISORDER SUB-COMMITTEE OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT
BP-023	A.D. Cohen	SAFETY AND EFFICACY OF CARFILZOMIB (CFZ) IN PREVIOUSLY-TREATED SYSTEMIC LIGHT-CHAIN (AL) AMYLOIDOSIS
BP-024	E. Kastritis	A RANDOMIZED PHASE III TRIAL OF MELPHALAN AND DEXAMETHASONE (MDEX) VERSUS BORTEZOMIB, MELPHALAN AND DEXAMETHASONE (BMDEX) FOR UNTREATED PATIENTS WITH AL AMYLOIDOSIS
BP-025	A. Wechalekar	INTERIM ANALYSIS OF ALCHEMY – A PROSPECTIVE STUDY OF 1000 PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS
BP-026	G. Merlini	PHASE 3 STUDY OF THE ORAL PROTEASOME INHIBITOR IXAZOMIB FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS: TOURMALINE-AL1
BP-027	S.A. Holstein	ANALYSIS OF SECOND PRIMARY MALIGNANCIES (SPMS) IN CALGB (ALLIANCE)/ECOG/BMT CTN 100104
BP-028	E.M. Haas	SYSTEMATIC CLASSIFICATION OF DEATH CAUSES IN MULTIPLE MYELOMA PATIENTS TREATED WITH HIGH-DOSE THERAPY
BP-029	B. Major	COMBINING EFFICACY AND TOXICITY EFFECT SIZES FROM RANDOMIZED CLINICAL TRIALS (RCTS) INTO AN INTERPRETABLE QUALITY-ADJUSTED EFFECT SIZE ESTIMATE IN PATIENTS WITH MULTIPLE MYELOMA (MM)
BP-030	A. Drawid	IMPACT OF NOVEL THERAPIES ON MULTIPLE MYELOMA SURVIVAL – CURRENT AND FUTURE OUTCOMES
POSTER SESSION		
PO-164	J. Jones	GUIDELINES FOR THE CORRECT DETERMINATION OF SECOND PRIMARY MALIGNANCIES IN MYELOMA TRIALS
PO-165	X. Leleu	LEVELS OF DISCORDANCE BETWEEN PATIENTS' AND PHYSICIANS' PERCEPTIONS OF PATIENTS' HEALTH-RELATED QUALITY OF LIFE (HRQL) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) – A CROSS-CULTURAL PERSPECTIVE
PO-166	R.T. Kamble	ORTHOTOPIC HEART TRANSPLANT FACILITATED AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN LIGHT-CHAIN AMYLOIDOSIS

PO-167	K. Celotto	THE EFFECT OF BORTEZOMIB TREATMENT ON ANTIBODY TITERS AGAINST COMMON VIRAL AND VACCINE ANTIGENS	PO-182	P. Mollee	CARDIAC AMYLOID IMAGING WITH 18F-FLORBETABEN POSITRON EMISSION TOMOGRAPHY: A PILOT STUDY
PO-168	J.M. Waldschmidt	CONDITIONAL SURVIVAL ANALYSIS OF MULTIPLE MYELOMA PATIENTS: EXPERIENCE OF THE COMPREHENSIVE CANCER CENTER FREIBURG (CCCF) UNIVERSITY MEDICAL CENTER FREIBURG	PO-183	J.W. Tan	DEVELOPMENT OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AFTER KIDNEY TRANSPLANT
PO-169	C. Chapuis Cellier	HEAVY CHAIN DISEASES: A RETROSPECTIVE STUDY	PO-184	P. Hsu	RISK OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH MULTIPLE MYELOMA RECEIVING NOVEL THERAPIES: A SINGLE ASIAN MEDICAL CENTER STUDY
PO-170	H. Landau	LESS THAN 30% OF RELAPSED LIGHT CHAIN (AL) AMYLOIDOSIS PATIENTS WITH PROGRESSIVE DISEASE REQUIRING THERAPY HAVE MEASURABLE SERUM FREE LIGHT CHAIN DIFFERENCES (DFLC): BETTER CRITERIA TO DEFINE HEMATOLOGIC PROGRESSION ARE NEEDED	PO-185	E. Fujii	POSSIBLE NEW DISEASE ENTITY OF AL AMYLOIDOSIS INDUCED BY DEPOSITION OF IGLC2
PO-171	A.A. Yusuf	SURVIVAL ANALYSIS IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS IN THE UNITED STATES MEDICARE DATABASE	PO-186	N. Abildgaard	CONTINUED IMPROVEMENT IN OVERALL SURVIVAL IN ELDERLY MULTIPLE MYELOMA PATIENTS AFTER 2008: A POPULATION BASED STUDY FROM THE DANISH MULTIPLE MYELOMA REGISTRY
PO-172	R.S. Go	CLINICAL PREVALENCE OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) IN THE UNITED STATES: ESTIMATING THE BURDEN ON HEALTH CARE	PO-188	A. Kato	IS THROMBOCYTOPHYLAXIS NECESSARY FOR MYELOMA PATIENTS? A CLINICAL DILEMMA AND PROPOSAL OF A PRACTICAL GUIDELINE
PO-173	E.E. Manasanch	CLINICAL CHARACTERISTICS, OUTCOMES AND PREDICTORS OF PROGRESSION TO MULTIPLE MYELOMA (MM) IN 61 PATIENTS WITH SOLITARY PLASMACYTOMA	PO-189	M.Y. Lee	VIRAL RESPIRATORY TRACT INFECTION IN PATIENTS WITH PLASMA CELL DISORDER IN CURRENT STANDARD TREATMENT
PO-174	A. D'Souza	VALIDATION OF THE 2012 HEMATOLOGIC RESPONSE CRITERIA IN LIGHT CHAIN AMYLOIDOSIS USING THE CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT (CIBMTR) DATABASE	PO-190	E. Moore	REAL WORLD MANAGEMENT OF MULTIPLE MYELOMA: INITIAL RESULTS FROM THE AUSTRALIA AND NEW ZEALAND MYELOMA AND RELATED DISEASES REGISTRY
PO-175	Y. Tsukune	THE INCIDENCE AND CLINICAL FEATURES OF HBV REACTIVATION IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS AND/OR ASCT: A RETROSPECTIVE MULTICENTER STUDY IN JAPAN	PO-191	J. Cid Ruzafa	PATIENT POPULATION WITH MULTIPLE MYELOMA AND TRANSITIONS ACROSS LINES OF THERAPY IN THE UNITED STATES: AN EPIDEMIOLOGIC MODEL
PO-176	R. De Tute	COLD AGGLUTININ DISEASE IS A PHENOTYPICALLY DISTINCT CLONAL B-CELL DISORDER	PO-192	N. Sekiguchi	UP-REGULATION OF TNFRSF13 AND HMGB1 IN WALDENSTROM MACROGLOBULINEMIA WITH OSTEOLYTIC BONE LESION
PO-177	R. De Tute	THE PRESENCE OF MYD88 L265P IN NON-IgM LYMPHOPLASMACYTIC LYMPHOMA: IMPLICATIONS FOR DIAGNOSIS AND THERAPY	PO-193	S. Sachchithanatham	HEAVY/LIGHT CHAIN IMMUNOPARESIS IDENTIFIES SYSTEMIC AL AMYLOIDOSIS PATIENTS WITH POOR SURVIVAL OUTCOMES
PO-178	M. Coyne	EVALUATING THE USE OF MULTIPARAMETRIC FLOW CYTOMETRY IN ESTABLISHING THE PRESENCE OF MINIMAL RESIDUAL DISEASE IN SYSTEMIC AL AMYLOIDOSIS: A REPORT OF EIGHT PATIENTS	PO-194	A. Benyounes	ADHERENCE TO ORAL IMMUNOMODULATORY THERAPY AT A COMMUNITY CANCER CENTER
PO-179	A.A. Yusuf	HOSPITALIZATION RATES FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS IN THE UNITED STATES MEDICARE DATABASE	PO-195	A. García Mateo	PROGNOSTIC VALUE OF HEVYLITE CHAIN IN A POPULATION COHORT OF MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE
PO-180	J. Ramzy	LECT2 AMYLOIDOSIS: NOT JUST A HISPANIC DISEASE	PO-196	M.M. Arruda	PREVALENCE OF THE ALTERATION OF THE RATIO KAPPA/LAMBDA BY FREELITE® IN BLOOD DONORS OVER FORTY YEARS OF AGE AT SANTA CASA OF SÃO PAULO: PRELIMINARY ANALYSIS
PO-181	C. Quinn	PROGRESSIVE INNOVATION IN ONCOLOGY: VALUING OUTCOMES BEYOND SURVIVAL	PO-197	B. Ballina	EXPECTANCY OF LIFE AND INCIDENCE RATE OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS: 15 YEARS RETROSPECTIVE ANALYSIS
			PO-198	V.H. Jimenez Zayas	CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORP) FOR THE TREATMENT OF AL AMYLOIDOSIS: EXPERIENCE

PO-199	R. Kaedbey	A RETROSPECTIVE ANALYSIS AT THE PRINCESS MARGARET CANCER CENTRE OF THE INITIAL THERAPY OF AL AMYLOIDOSIS: CYBORD VERSUS OTHER REGIMENS	PO-216	F. Almagro Torres	PRIMARY SYSTEMIC AMYLOIDOSIS ASSOCIATED WITH MULTIPLE MYELOMA. OUR EXPERIENCE
PO-200	C.K. Min	TREATMENT RESULTS OF VENOUS THROMBOEMBOLISM WITH DALTEPARIN IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING ANTI-MYELOMA CHEMOTHERAPEUTIC AGENTS	PO-217	S. Cerdá	SECOND MALIGNANCIES AND MULTIPLE MYELOMA. A SINGLE-INSTITUTION EXPERIENCE IN SPAIN
PO-201	R. Ria	SUBCUTANEOUS IMMUNOGLOBULIN FOR TREATMENT OF SECONDARY HYPOGAMMAGLOBULINEMIA IN MULTIPLE MYELOMA	PO-218	M. Krejci	SCLEREDEMA ASSOCIATED WITH MULTIPLE MYELOMA OR MGUS: TREATMENT REPORT OF FOUR CASES
PO-202	R. Pramanik	POEMS SYNDROME: A RETROSPECTIVE ANALYSIS OF CLINICOPATHOLOGICAL PROFILE AND TREATMENT OUTCOMES OF 43 CONSECUTIVE CASES FROM A TERTIARY CANCER CENTRE IN INDIA	PO-219	G. Mele	SUBCUTANEOUS BORTEZOMIB-INDUCED PARALYTIC ILEUS IN MULTIPLE MYELOMA PATIENTS
PO-203	J. Page	FOLLOWING THE GUIDELINES FOR REDUCING OSTEOECROSIS OF THE JAW ASSOCIATED WITH BIPHOSPHONATE THERAPY IN SYMPTOMATIC MULTIPLE MYELOMA - EXPERIENCE OF A DISTRICT GENERAL HOSPITAL	PO-220	M.B. Abid	DISSEMINATED CRYPTOCOCCAL INFECTION IN AN IMMUNOCOMPETENT HOST MIMICKING PLASMA CELL DISORDER: A CASE REPORT AND LITERATURE REVIEW
PO-204	C. Vadikoliou	SECONDARY MALIGNANCIES IN MULTIPLE MYELOMA	PO-221	G. Mele	POMALIDOMIDE AND DEXAMETHASONE ASSOCIATION IS AN EFFECTIVE SALVAGE THERAPY IN SECONDARY PLASMA CELL LEUKAEMIA (SPCL)
PO-205	E. Sahovic	AUTOLOGOUS HCT IN ELDERLY MYELOMA PATIENTS, AHNCI SINGLE INSTITUTION EXPERIENCE	PO-222	Z. Bolaman	THE IMPORTANCE OF FUNDUS EXAMINATION FOR FEVER ETIOLOGY IN A PATIENT WITH MYELOMA
PO-206	S. Mahmood	BLEEDING DIATHESIS AND PROTHROMBOTIC TENDENCIES IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LIGHT CHAIN AMYLOIDOSIS: IMPORTANT CLINICAL IMPLICATIONS	PO-223	N. Shanmuganathan	CASE STUDY: AN EXAMPLE OF MANUAL PLASMA EXCHANGE IN A CHALLENGING PATIENT WITH HYPERVISCOACITY SECONDARY TO WALDENSTROM'S MACROGLOBULINAEMIA
PO-207	V. Maisnar	CZECH MYELOMA GROUP REGISTRY OF MONOCLONAL GAMMOPATHIES			
PO-208	F. Almagro Torres	PLASMA CELL LEUKEMIA. EXPERIENCE IN OUR CENTER			
PO-209	O.G. Sevindik	QUALITY OF LIFE IN MULTIPLE MYELOMA: VALIDATION OF THE TURKISH VERSION OF THE QLQ-MY20 INSTRUMENT			
PO-210	Y. Yoshiki	THE VERIFICATION OF RENAL PROGNOSIS OF ALAMYLOIDOSIS			
PO-211	P.P. Kotoucek	FINDING THE MEANING OF LIFE OF PATIENTS WITH MULTIPLE MYELOMA CORRELATES WITH BETTER CONTROL OF THEIR DISEASE BY CHEMOTHERAPY			
PO-212	A. Vicent Castelló	INCIDENCE OF NEUROPATHY IN PATIENTS TREATED WITH BORTEZOMIB SUBCUTANEOUS			
PO-213	A. Alegre	MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE (MGRS).HEMATOLOGICAL AND RENAL COMPLETE RESPONSE WITH BORTEZOMIB			
PO-214	F. Escalante	SAFETY AND ADHESION WITH SUBCUTANEOUS BORTEZOMIB TREATMENT IN MULTIPLE MYELOMA			
PO-215	A. Garcia-Guiñón	INCIDENCE OF PERIPHERAL NEUROPATHY IN CLINICAL PRACTICE IN MULTIPLE MYELOMA PATIENTS TREATED WITH REGIMENS WITH			

4. Multiple Myeloma Biology, Pathophysiology, Preclinical Studies, Bone Disease

POSTER DISCUSSION SESSION

Chairman: Noopur Raye

BP-031	E. Dhimolea	FUNCTIONAL MAPPING OF MULTIPLE MYELOMA KINOME WITH LIBRARY OF SMALL MOLECULE INHIBITORS
BP-032	Y.X. Zhu	IDENTIFICATION OF FAM46C AS A TUMOR SUPPRESSOR IN MULTIPLE MYELOMA
BP-033	S. Parekh	TARGETING MYC VIA ARK5 IN MULTIPLE MYELOMA
BP-034	S. Janz	ADOPTIVE B-CELL TRANSFER MOUSE MODEL OF HUMAN MYELOMA
BP-035	H. Suen	CYTOTOXIC CD8+ T CELLS IN MYELOMA ARE IN A STATE OF TELOMERE-INDEPENDENT SENESENCE RATHER THAN AN EXHAUSTED OR ANERGIC STATE: IMPLICATION FOR IMMUNE CHECKPOINT BLOCKADE
BP-036	T. Gogishvili	ANTI-MYELOMA ACTIVITY OF CS-1-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) EXPRESSING T CELLS IN VITRO AND IN PRECLINICAL IN VIVO MODELS
BP-037	E. Viziteu	ROLE OF RECQ1 HELICASE IN MULTIPLE MYELOMA DRUG RESISTANCE
BP-038	T. Perini	A PLASTIC SQSTM1/P62-DEPENDENT AUTOPHAGIC RESERVE MAINTAINS PROTEIN HOMEOSTASIS AND DETERMINES PROTEASOME INHIBITOR SUSCEPTIBILITY IN MULTIPLE MYELOMA CELLS
BP-039	A. Reale	TOP2A KNOCKDOWN RESENSITIZES CARFILZOMIB-RESISTANT HMCLS TO CARFILZOMIB
BP-040	P. Neri	IMiDS INDUCED IKAROS-DEPENDENT DOWNREGULATION OF MYC IN MYELOMA IS MEDIATED THROUGH THE REPRESSION OF THE 3' IGH ENHANCER ACTIVITY AND THE NURD COMPLEX REPOSITIONING
POSTER SESSION		
PO-224	C. Giallongo	GRANULOCYTE-LIKE MYELOID DERIVED SUPPRESSOR CELLS (G-MDSCs) ARE INCREASED IN MULTIPLE MYELOMA DUE TO IMMUNOLOGICAL DYSREGULATION OF MESENCHYMAL STEM CELLS (MSCs)
PO-225	I. Savvidou	TARGETING THE WNT CANONICAL PATHWAY IN MULTIPLE MYELOMA (MM) WITH BC2059, A NEW ORALLY BIOAVAILABLE B-CATENIN INHIBITOR
PO-226	T. Khong	TRAMETINIB COMBINED WITH DEXAMETHASONE INDUCES BIM-DEPENDENT SYNERGISTIC KILLING OF PREVIOUSLY DEXAMETHASONE REFRACTORY MYELOMA
PO-227	V.C. Ramani	TARGETING HEPARANASE TO INHIBIT MYELOMA CHEMORESISTANCE
PO-228	C. Pawlyn	EZH2 OVEREXPRESSION IN MYELOMA PATIENTS SHORTENS SURVIVAL AND IN-VITRO DATA SUPPORTS A POTENTIAL NEW TARGETED TREATMENT STRATEGY
PO-229	S. Hernández-García	FILANESIB (ARRY-520) DEMONSTRATES POTENT AND RAPID ACTIVITY IN PRECLINICAL MODELS OF MM, DEPENDENT ON BCL-2 FAMILY EXPRESSION, AND SYNERGISTIC WITH DEXAMETHASONE AND IMiDS
PO-230	M. Ishibashi	REVERSE SIGNALING VIA B7-H1/PD-1 INTERACTION AND CLINICAL CHARACTERISTICS OF B7-H1 (PD-L1) EXPRESSED ON MULTIPLE MYELOMA CELLS
PO-231	J. Devin	INHIBITION OF H3K9 METHYLTRANSFERASE AS A POTENT THERAPEUTIC TARGET IN MULTIPLE MYELOMA
PO-232	F. Fan	THE AP-1 TRANSCRIPTION FACTOR JUNB PROMOTES MULTIPLE MYELOMA (MM) CELL PROLIFERATION, SURVIVAL AND DRUG RESISTANCE IN THE BONE MARROW MICROENVIRONMENT
PO-233	D. Quwaider	A NOVEL FUNCTION OF DEPTOR IN MULTIPLE MYELOMA: COMMITMENT TO PLASMA CELL MATURATION
PO-234	Y. Qin	MIR-137 CONTRIBUTES TO DRUG SUSCEPTIBILITY AND CHROMOSOMAL INSTABILITY OF MULTIPLE MYELOMA THROUGH TARGETING AURKA
PO-235	M. Zangari	SURGICAL CONTROL/CURE OF 5TGM1 MURINE MULTIPLE MYELOMA MODEL BY THYROPATHYROIDECTOMY
PO-236	Z. Xie	MMSET 1 ACTS AS AN ONCOGENE IN T(4;14) MULTIPLE MYELOMA CELLS
PO-237	H. Miki	EFFECTIVE IMPAIRMENT OF MYELOMA PROGENITORS BY HYPERETHERMIA: AUGMENTATION WITH BORTEZOMIB AND PIM INHIBITION IN COMBINATION
PO-238	A.A. López-Iglesias	PRECLINICAL ANTIMYELOMA ACTIVITY OF EDO-S101
PO-239	M.C. Rapanotti	BONE MARROW ANGIOGENIC POTENTIAL AND MOLECULAR EXPRESSION OF CELL-CELL ADHESION MOLECULES AND MATRIX-METALLO PROTEINASES IN MULTIPLE MYELOMA
PO-240	S. Yousef	CANCER-TESTIS ANTIGEN SLLP1 REPRESENTS A PROMISING TARGET FOR THE IMMUNOTHERAPY OF MULTIPLE MYELOMA
PO-241	P. Abdollahi	PRL-3 INCREASES SURVIVAL OF MULTIPLE MYELOMA CELLS THROUGH SRC ACTIVATION
PO-242	K. Klausz	A NOVEL HUMAN FC-OPTIMIZED ICAM-1/CD54 ANTIBODY (MSH-TP15E) WITH POTENT ANTI-MYELOMA ACTIVITY IN VITRO AND IN VIVO

PO-243	Y.X. Zhu	IDENTIFICATION OF FAM46C AS A TUMOR SUPPRESSOR IN MULTIPLE MYELOMA	PO-259	A. Bolomsky	TARGETING OF BMI-1 BY THE SMALL MOLECULE INHIBITOR PTC-209 DEMONSTRATES POTENT ANTI-MYELOMA ACTIVITY IN VITRO
PO-244	T. Paño	THE NOVEL PAN-PIM KINASE INHIBITOR, LGH447, SHOWS DUAL ANTI-TUMORAL AND BONE ANTIRESORPTIVE EFFECT IN MULTIPLE MYELOMA AND SYNERGIZES WITH STANDARD-OF-CARE TREATMENTS	PO-260	M. Westrin	GDF15 PROMOTES OSTEOCLAST DIFFERENTIATION AND HIGH SERUM GDF15 LEVELS ARE ASSOCIATED WITH MULTIPLE MYELOMA BONE DISEASE
PO-245	J. Brayer	HISTONE DEACETYLASE 11 (HDAC11) IS CRITICAL FOR PLASMA CELL DEVELOPMENT AND MULTIPLE MYELOMA SURVIVAL	PO-261	R. Bajpai	TARGETING METABOLISM IN MULTIPLE MYELOMA ENHANCES BIM BINDING TO BCL-2 ELICITING SYNTHETIC LETHALITY TO ABT-199
PO-246	A. Artech	MULTIPLE MYELOMA (MM) PATIENTS IN LONG TERM COMPLETE REMISSION (LCR) AFTER AUTOLOGUS TRANSPLANTATION EXPRESS A DISTINCTIVE IMMUNE "FOOTPRINT". A SINGLE CENTRE EXPERIENCE	PO-262	H. Quach	GRP78 (78-KDA GLUCOSE-REGULATED PROTEIN) IS A POTENTIALLY USEFUL BIOMARKER FOR PREDICTING RESPONSE AND SURVIVAL OUTCOME IN PATIENTS WITH MULTIPLE MYELOMA, AND IS A POTENTIALLY USEFUL TARGET IN THE TREATMENT OF MULTIPLE MYELOMA
PO-247	E. Terpos	HIGH LEVELS OF PERIOSTIN IN PATIENTS WITH MULTIPLE MYELOMA CORRELATE WITH LOW BONE FORMATION, INCREASED FRACTURE RATE AND DIFFUSE MRI PATTERN	PO-263	L. Besse	BORTEZOMIB- AND CARFILZOMIB-RESISTANT MULTIPLE MYELOMA CELLS GENERATED IN VITRO MATCH THE MOLECULAR HALLMARKS OF BORTEZOMIB-RESISTANT PRIMARY MYELOMA CELLS, BUT DIFFER IN THEIR SENSITIVITY TO BORTEZOMIB, CARFILZOMIB AND NOVEL PROTEASOME INHIBITING DRUGS
PO-248	J.M. Waldschmidt	A NOVEL 3D HIGH-THROUGHPUT COCULTURE PLATFORM FOR MULTIPLE MYELOMA EX-VIVO SENSITIVITY TESTING AND DRUG SCREENING	PO-264	N. Aouali	L-PLASTIN FUNCTION IN DRUG RESISTANCE AND IMMUNE SYSTEM RESISTANCE
PO-249	M. Nikiforov	MULTIPLE MYELOMA DRUG RESISTANCE: ALL ROADS LEAD TO KLF9	PO-265	S. Garavelli	NOTCH SIGNALING DYSREGULATION PROMOTES MULTIPLE MYELOMA-ASSOCIATED BONE DISEASE
PO-250	E. Kastiris	OSTEOPROTEGERIN IS A SIGNIFICANT PROGNOSTIC FACTOR FOR OVERALL SURVIVAL IN PATIENTS WITH PRIMARY SYSTEMIC AMYLOIDOSIS INDEPENDENT OF THE MAYO STAGING	PO-266	S. Galletti	NOTCH PATHWAY AND INTELLEUKIN-6 COOPERATE TO SUPPORT MULTIPLE MYELOMA CELL PROLIFERATION
PO-251	H.M. Nurul	THE KCA2.3 POTASSIUM CHANNEL AT 1Q21 IS ASSOCIATED WITH DISEASE PROGRESSION AND REDUCED SURVIVAL DURING RELAPSE IN MULTIPLE MYELOMA	PO-267	C. Gu	FOXMI IS A THERAPEUTIC TARGET IN HIGH-RISK MULTIPLE MYELOMA
PO-252	Y. Mishima	IN VIVO FLUORESCENT IMAGING OF MULTIPLE MYELOMA IN TRANSPARENTIZING XENOGRFT MODEL	PO-268	G. Rozic	STK405759 AS A NOVEL DRUG FOR MULTIPLE MYELOMA THERAPY
PO-253	E. Lozano	CHARACTERIZATION OF TCR REPERTOIRE OF CD4+ AND CD8+ T CELLS FROM PATIENTS WITH MULTIPLE MYELOMA IN SUSTAINED COMPLETE REMISSION	PO-269	M. Beksac	FREQUENCY OF PROTEASE ACTIVATED RECEPTOR1 (PAR1) EXPRESSION AND THE IN VITRO EFFECTS OF XT5 AND XT2B, TWO NOVEL PAR1 BINDING MOLECULES, ON PRIMARY AND BORTEZOMIB REFRACTORY MYELOMA CELL LINES
PO-254	E. De Smedt	RASSF4 FUNCTIONS AS A TUMOR SUPPRESSOR IN MULTIPLE MYELOMA	PO-270	K. Jung	CO-INHIBITORY MOLECULE VSIG4 NEGATIVELY REGULATES HELPER T CELL-DEPENDENT ISOTYPE SWITCHING AND ANTIBODY RESPONSE
PO-255	M. Colombo	NOTCH SIGNALING DRIVES MYELOMA CELLS HOMING TO THE BONE MARROW BY REGULATING THE CXCR4/CXCL12 AXIS	PO-271	D. Tibullo	BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND BONE RESORPTION THROUGH MODULATION OF CHIT1 AND YKL40 EXPRESSION
PO-256	A. Brown	IDENTIFYING DISEASE PROGRESSION EVENTS IN MULTIPLE MYELOMA	PO-272	M. Asahi	SURVIVIN SUPPRESSANT YM155 INDUCES CELL DEATH VIA PROTEASOMAL DEGRADATION OF C-MYC IN MULTIPLE MYELOMA CELLS
PO-257	E. Terpos	SCLEOSTIN REMAINS ELEVATED EVEN IN THE PLATEAU PHASE OF MYELOMA PATIENTS: IMPLICATIONS INTO THE PATHOGENESIS OF OSTEOBLAST DYSFUNCTION OF MULTIPLE MYELOMA	PO-273	S. Yousef	CD229 IS EXPRESSED ON THE SURFACE OF PLASMA CELLS CAPRYNG AN ADHERANT, PLURIPOTENT AND CLONALLY
PO-258	T. Diaz	BET BROMODOMAIN BLOCKADE ENHANCES IKAROS INHIBITION BY LENALIDOMIDE THERAPY PROVIDING ADDITIONAL ACTIVITY IN			

PO-274	A. Bolomsky	THE CHEMOKINE CXCL9 (MIG) IS AN INDEPENDENT PREDICTOR OF OVERALL SURVIVAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA	PO-289	S. Shah	CHARACTERIZATION OF HEAT SHOCK FACTOR 1 IN RESPONSE TO PROTEASOME INHIBITION UNVEILS A NOVEL THERAPEUTIC STRATEGY FOR MULTIPLE MYELOMA TREATMENT
PO-275	K.M. Mrozik	N-CADHERIN IS A THERAPEUTIC TARGET IN T(4;14)-POSITIVE MULTIPLE MYELOMA	PO-290	E. Fujii	BUFLALIN INDUCES APOPTOSIS IN MYELOMA CELLS THROUGH DNA DAMAGE AT HYPOXIC CONDITIONS
PO-276	S. Thangavadiel	MYELOMA-DERIVED CCL27 INDUCES STROMA-DEPENDENT RESISTANCE AGAINST BORTEZOMIB VIA UPREGULATION OF IL-10	PO-291	A. Leivas	AUTOLOGOUS ACTIVATED AND EXPANDED NATURAL KILLER CELLS DESTROY MULTIPLE MYELOMA CLONOGENIC TUMOR CELLS THROUGH NKG2D AND ITS LIGANDS
PO-277	L. Zhang	POTENTIAL ROLE OF EXOSOME-ASSOCIATED MICRORNA PANELS AND IN VIVO ENVIRONMENT TO PREDICT DRUG RESISTANCE FOR PATIENTS WITH MULTIPLE MYELOMA IN THE ERA OF NOVEL AGENTS: A RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA FROM A CHINESE CENTER OF HEMATOLOGICAL DISEASE	PO-292	S. Morita	CLINICOPATHOLOGICAL ANALYSIS OF MULTIPLE MYELOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT
PO-278	I. Saltarella	INVOLVEMENT OF NOTCH SIGNALING IN MULTIPLE MYELOMA ANGIOGENESIS AND PROGRESSION	PO-293	F. Costa	LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MENSENCHYMAL STROMAL CELL INHIBITORY PROPERTIES BY IKAROS DEPENDENT AND INDEPENDENT MECHANISMS
PO-279	A. Lamanuzzi	INHIBITION OF MTOR AS AN ANGIOGENIC STRATEGY IN MULTIPLE MYELOMA	PO-294	O. Decaux	COMPARISON OF POLYCLONAL AND MONOCLONAL ANTIBODY BASED FREE LIGHT CHAIN ASSAYS TAKING ACCOUNT OF RENAL FUNCTION
PO-280	J. Minarik	CORRELATION OF THE PARAMETERS OF MYELOMA BONE DISEASE SIGNALING TO THE ACTIVITY OF MULTIPLE MYELOMA AND TO THE RISK OF TRANSFORMATION IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE	PO-295	G.N. Le	STRUCTURAL CHARACTERISATION OF IMMUNOGLOBULIN G GLYCOSYLATION IN MULTIPLE MYELOMA
PO-281	D. Tibullo	ROLE OF NUCLEAR HEME OXYGENASE 1 (HO-1) IN BORTEZOMIB INDUCED CELL DEATH AND GENOMIC INSTABILITY OF MULTIPLE MYELOMA (MM) CELLS	PO-296	H. Park	C-MET ASSOCIATED WITH OSTEOGENESIS IN MULTIPLE MYELOMA PATIENTS BY INDUCTION OF MMP9 EXPRESSION BY HGF IN BMSCS
PO-282	L.J. Crawford	HUWE1 IS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA	PO-297	A. Jungbluth	EXPRESSION OF CANCER TESTIS ANTIGENS (CTAS) IN PLASMACYTOMA WITH AND WITHOUT BONE MARROW INVOLVEMENT
PO-283	A. Yamada	EXPRESSION AND FUNCTION OF SLAM FAMILY MOLECULE SLAMF3 (CD229) IN MYELOMA	PO-298	M. Hao	INCREASED DNP73 PROMOTES MYELOMA CELL GROWTH AND REPPRESSES DNA DAMAGE-INDUCED APOPTOSIS
PO-284	M. Gkotzamani dou	DEFICIENCY IN DNA REPAIR PATHWAYS OF PERIPHERAL BLOOD MONONUCLEAR CELLS CORRELATES WITH BETTER CLINICAL OUTCOME OF MYELOMA PATIENTS	PO-299	X. Qin	CLONAL EVOLUTIONAL PATHS IN MULTIPLE MYELOMA REVEALED IN SINGLE CELL OF SEQUENTIAL ANALYSIS AND ITS CLINICAL SIGNIFICANCE
PO-285	N. Shingen	ALTERATION OF PIM-2 EXPRESSION BY CLINICALLY AVAILABLE ANTI-MYELOMA AGENTS: COMBINATORY ANTI-MYELOMA EFFECTS WITH PIM INHIBITION	PO-300	C.K. Min	IMPACT OF LENALIDOMIDE AND DEXAMETHASONE TREATMENT ON IMMUNE CELL POPULATIONS OF THE PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA
PO-286	E. Grywalska	RELATION BETWEEN LYMPHOCYTES AND DENDRITIC CELLS - IMPLICATIONS FOR THE EFFECTIVENESS OF AN IMMUNE RESPONSE TO NEOPLASTIC ANTIGENS IN PATIENTS SUFFERING FROM MULTIPLE MYELOMA	PO-301	Y. Jian	TARGET AND RESISTANCE RELATED PROTEINS OF RECOMBINATE MUTANT HUMAN TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND (RHMTRAIL) ON MYELOMA CELL LINES
PO-287	X. Qu	THE MECHANISMS AND EFFECTS OF LONG NONCODING RNA MATERNALLY EXPRESSED 3 IN MULTIPLE MYELOMA	PO-302	E. Rojas	AMILORIDE INDUCES POTENT ANTITUMORAL ACTIVITY IN MULTIPLE MYELOMA THROUGH THE REACTIVATION OF MUTANT P53
PO-288	P.G. Richardson	THE CURRENT UNMET MEDICAL NEEDS IN THE TREATMENT AND MANAGEMENT OF MULTIPLE MYELOMA (MM)	PO-303	M. Zang	CDC37 SUPPRESSING IN MULTIPLE MYELOMA BLOCKS PROLIFERATION BUT INDUCES BORTEZOMIB RESISTANCE
			PO-304	S. Jasrotia	SERUM CYTOKINE LEVELS IN PATIENTS OF MULTIPLE MYELOMA AT DIAGNOSIS AND AT RELAPSE

PO-305	K. Han	A NOVEL SMALL MOLECULE COMPOUND DISPLAYS PRECLINICAL ACTIVITY AGAINST MULTIPLE MYELOMA BY DISRUPTING THE MTOR SIGNALING PATHWAY
PO-306	J. Minarik	THE RELATIONSHIP OF MYELOMA BONE DISEASE SIGNALLING TO THE PARAMETERS OF BONE METABOLISM IN MONOCLONAL GAMMOPATHIES
PO-307	M.J. Streetly	MYELOMA IS ASSOCIATED WITH FEATURES OF METABOLIC SYNDROME
PO-308	C. Geraldes	NEW TARGETED DRUGS IN MULTIPLE MYELOMA THERAPY - IN VITRO STUDIES
PO-309	J. Minarik	THE RELATIONSHIP OF THE PARAMETERS OF MYELOMA BONE DISEASE SIGNALLING PATHWAYS TO THE EXTENT OF BONE INVOLVEMENT AND EXTRAMEDULLARY DISEASE IN MONOCLONAL GAMMOPATHIES
PO-310	E. Le Mouel	USE OF PROTEIN-TO-CREATININE RATIO IN SPOT URINE SAMPLES FOR THE EVALUATION OF PROTEINURIA IN PATIENTS WITH MULTIPLE MYELOMA
PO-311	H.M.M. Ali	IMMUNE AND HORMONAL PECULIARITIES AND GENDER RELATED CHANGES IN MULTIPLE MYELOMA PATIENTS
PO-312	K. Suzuki	CLINICAL SIGNIFICANCE OF GRANULES IN CYTOPLASM OF NEWLY DIAGNOSED MYELOMA CELLS

5. Multiple Myeloma Therapy in Newly Diagnosed Patients excluding Transplantation

POSTER DISCUSSION SESSION

Chairman: Heinz Ludwig

BP-041	V. Magarotto	LENALIDOMIDE-DEXAMETHASONE OR MELPHALAN-LENALIDOMIDE-PREDNISONE (MPR) OR CYCLOPHOSPHAMIDE-PREDNISONE-LENALIDOMIDE (CPR) FOR INITIAL TREATMENT OF REAL LIFE ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
BP-042	S.G.R. Vereist	AGE VERSUS FRAILTY: WHAT SHOULD DETERMINE TREATMENT CHOICE IN THE ELDERLY MYELOMA PATIENTS THESE DAYS?
BP-043	S. Bringhen	WEEKLY CARFILZOMIB IN COMBINATION WITH CYCLOPHOSPHAMIDE AND DEXAMETHASONE (WCCYD) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): A PHASE 1/2 STUDY OF THE EUROPEAN MYELOMA NETWORK TRIALIST GROUP
BP-044	J.G. Berdeja	BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BBD) AS FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM) WHO ARE NOT CANDIDATES FOR HIGH DOSE CHEMOTHERAPY
BP-045	E. Lee	9-YEAR FOLLOW-UP BORTEZOMIB, THALIDOMIDE, DEXAMETHASONE INDUCTION THERAPY FOLLOWED BY MELPHALAN, PREDNISOLONE, THALIDOMIDE CONSOLIDATION THERAPY AS A FIRST LINE OF TREATMENT FOR PATIENTS WITH MULTIPLE MYELOMA WHO ARE NON-TRANSPLANT CANDIDATES: RESULTS OF THE KOREAN MULTIPLE MYELOMA WORKING PARTY (KMMWP)
BP-046	M.H. Qazilbash	RANDOMIZED PHASE II TRIAL OF COMBINATION IDIOTYPE VACCINE AND ANTI-CD3/ANTI-CD28 COSTIMULATED AUTOLOGOUS T CELLS IN PATIENTS WITH MULTIPLE MYELOMA POST-AUTOTRANSPLANTATION
BP-047	M.H. Qazilbash	A RANDOMIZED PHASE III TRIAL OF BUSULFAN + MELPHALAN (BU-MEL) VS MELPHALAN ALONE FOR MULTIPLE MYELOMA: LONGER PFS IN THE BU-MEL ARM
BP-048	M.V. Mateos	MATCHED-PAIRS ANALYSIS OF OUTCOMES WITH BORTEZOMIB, MELPHALAN, AND PREDNISONE (VMP) TREATMENT FOR PREVIOUSLY UNTREATED MULTIPLE MYELOMA (MM) USING LONG-TERM FOLLOW-UP DATA FROM THE PHASE 3 VISTA AND PETHEMA/GEM05 TRIALS
BP-049	H.S. Lee	CLINICAL IMPACT OF DEPTH OF RESPONSE ON 3 MONTHS AFTER STARTING CHEMOTHERAPY AND CUMULATIVE DOSE OF BORTEZOMIB ON SURVIVAL IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA WHO TREATED WITH BORTEZOMIB COMBINED MELPHALAN PLUS PREDNISOLONE ; HOW TO IMPROVE SURVIVAL RATES BY LONGER DURATION OF TREATMENT AND EARLY DEEPER RESPONSE
BP-050	H. Giles	HIGH VERSUS ATTENUATED DOSE DEXAMETHASONE HAS LITTLE EFFECT ON THE SPEED OR DEPTH OF RESPONSE TO INDUCTION

POSTER SESSION

- PO-313** L. Rosiñol
TREATMENT OF RENAL FAILURE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WITH BORTEZOMIB AND DEXAMETHASONE: RESULTS OF A PHASE II TRIAL FROM PETHEMA/GEM GROUP (RENVEL)
- PO-314** M. Takeuchi
RAPID REDUCTION IN IFLC PREDICTS ACHIEVEMENT OF VGPR AFTER 4 CYCLES OF VCD TREATMENT: SHIMOUSA MM-01 VCD STUDY
- PO-315** S. Usmani
LENALIDOMIDE DOSE MODIFICATIONS AND ASSOCIATED PATIENT OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
- PO-316** V. Martínez Robles
INTENTION TO TREAT VS AGE OF DIAGNOSIS. ANALYSIS OF BENEFICIAL EFFECT OF NEW AGENTS IN THE TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
- PO-317** S.R. Arlikian
PATTERNS OF GROWTH FACTOR COSTS IN MULTIPLE MYELOMA PATIENTS TREATED WITH LENALIDOMIDE OR BORTEZOMIB
- PO-318** C.P. Venner
CYCLOPHOSPHAMIDE, BORTEZOMIB AND DEXAMETHASONE (CYBORD) FOR THE UPFRONT THERAPY OF TRANSPLANT INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA
- PO-319** J.R. Espinoza Zamora
SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA IN FIRST-LINE TREATMENT: THALIDOMIDE, DEXAMETHASONE AND ZOLEDRONIC ACID: REPORT OF THE NATIONAL CANCER INSTITUTE OF MÉXICO (INCAN)
- PO-320** M.F. Martínez García
INCIDENCE AND CHARACTERISTICS OF BACTERIAL INFECTIONS DURING INDUCTION THERAPY IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH NEW DRUGS. A STUDY OF 67 PATIENTS FROM A SINGLE INSTITUTION
- PO-321** Y. Kusano
CYBORD DEMONSTRATED ITS SUPERIORITY TO BORTEZOMIB PLUS DEXAMETHASONE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
- PO-322** S.K. Sohn
OUTCOMES BETWEEN FRONTLINE AND SALVAGE BORTEZOMIB-BASED REGIMENS IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA
- PO-323** M.T. Abad
RESULTS OF THE PROTOCOL VCD FOR MULTIPLE MYELOMA IN A SINGLE CENTER IN ALGERIA
- PO-324** H.J. Shin
IMPROVED OUTCOME BY EARLY DOSE REDUCTION AND SCHEDULE ADJUSTMENT WITH SUBCUTANEOUS INJECTION OF BORTEZOMIB IN ELDERLY MYELOMA PATIENTS RECEIVING BORTEZOMIB-MELPHALAN-PREDNISONE REGIMEN

6. Multiple Myeloma Therapy Relapsed/Refractory Patients

POSTER DISCUSSION SESSION

Chairman: Torben Plesner

- BP-051** A. Palumbo
EFFICACY AND SAFETY OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRd) VS LENALIDOMIDE AND DEXAMETHASONE (RD) IN PATIENTS (PTS) WITH RELAPSED MULTIPLE MYELOMA (RMM) BASED ON AGE: SECONDARY ANALYSIS FROM THE PHASE 3 STUDY ASPIRE (NCT01080391)
- BP-052** A.K. Stewart
SUPERIOR HEALTH-RELATED QUALITY OF LIFE WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA (MM): RESULTS FROM THE ASPIRE TRIAL
- BP-053** M.A. Dimopoulos
STRATUS™ (MM-010): A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE (POM) + LOW-DOSE DEXAMETHASONE (LODEX) IN PATIENTS (PTS) WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
- BP-054** P. Moreau
SURVIVAL OUTCOMES IN PATIENTS (PTS) WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE MM-003 TRIAL: IMPACT OF STABLE DISEASE (SD) AS A RESPONSE TO POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (POM + LODEX)
- BP-055** P.G. Richardson
SUBGROUP ANALYSIS BY PRIOR TREATMENT OF THE EFFICACY AND SAFETY OF PANOBINOSTAT PLUS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN THE PANORAMA 1 STUDY
- BP-056** S. Lonial
SAFETY PROFILE OF ORAL IXAZOMIB: EXPERIENCE FROM 761 PATIENTS (PTS) ACROSS 14 PHASE 1 OR PHASE 1/2 CLINICAL STUDIES
- BP-057** X.S. Xu
EXPOSURE-RESPONSE RELATIONSHIP OF DARATUMUMAB EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM) AFTER PRIOR PROTEASOME INHIBITORS (PIS) AND IMMUNOMODULATORY DRUGS (IMiDs)
- BP-058** M.S. Raab
A PHASE I/IIA STUDY OF THE HUMAN CD38 ANTIBODY MOR202 (MOR3087) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
- BP-059** P.G. Richardson
IBRUTINIB IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY AND REFRACTORY MULTIPLE MYELOMA: RESULTS FROM A MULTICENTER PHASE 2 TRIAL
- BP-060** S. Kumar
PHASE I INTERIM SAFETY AND EFFICACY OF VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY FOR RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM)

POSTER SESSION

PO-325	M. Cavo	ADVERSE EVENT (AE) MANAGEMENT WITH POMALIDOMIDE (POM) + LOW-DOSE DEXAMETHASONE (LODEX) IN THE STRATUS™ TRIAL: A PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY IN PATIENTS (PTS) WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)	P. Richardson	PHASE 1/2 DOSE-ESCALATION STUDY OF MARIZOMIB (MRZ, NPI-0052) PLUS LOW DOSE DEXAMETHASONE (DEX) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA; STUDY NPI-0052-101 (NCT00461045)
PO-326	P. Sonneveld	TREATMENT (TX) WITH POMALIDOMIDE (POM) AND LOW-DOSE DEXAMETHASONE (LODEX) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IMPAIRMENT (RI) INCLUDING THOSE ON DIALYSIS	C. Touzeau	PHASE 1B INTERIM RESULTS: VENETOCLAX (ABT-199/GDC-0199) IN COMBINATION WITH BORTEZOMIB (BTZ) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM)
PO-327	J. Matous	A PHASE 1 STUDY OF THE PHARMACOKINETICS (PK) AND SAFETY OF POMALIDOMIDE + LOW-DOSE DEXAMETHASONE (POM+LODEX) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IMPAIRMENT (RI)	C. Paba Prada	OPROZOMIB (OPZ) AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY
PO-328	K. Weisel	OUTCOMES OF PATIENTS (PTS) WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IMPAIRMENT (RI) TREATED WITH POMALIDOMIDE (POM) + LOW-DOSE DEXAMETHASONE (LODEX) IN THE PHASE 3B STRATUS™ TRIAL (MM-010)	M. Mohty	OUTCOME OF FIRST SALVAGE THERAPY FOR MULTIPLE MYELOMA (MM) IN REAL-WORLD CLINICAL PRACTICE: RESULTS FROM THE THIRD INTERIM ANALYSIS OF THE MULTINATIONAL, OBSERVATIONAL, NON-INTERVENTIONAL EMMOS STUDY
PO-329	A. Palumbo	EFFECT OF AGE ON OUTCOMES WITH POMALIDOMIDE (POM) + LOW-DOSE DEXAMETHASONE (LODEX) IN PATIENTS (PTS) WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE STRATUS™ TRIAL (MM-010), A SINGLE-ARM, PHASE 3B STUDY	A. Chari	THE BRUTON'S TYROSINE KINASE INHIBITOR IBRUTINIB IN COMBINATION WITH CARFILZOMIB IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: INITIAL RESULTS FROM A MULTICENTER PHASE 1/2B STUDY
PO-330	M. Dimopoulos	ELOTUZUMAB: SERUM PROTEIN ELECTROPHORESIS AND IMMUNOFIXATION INTERFERENCE WITH CLINICAL ASSESSMENT OF MYELOMA (RRMM) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)	A. Keller	VORINOSTAT (V), BORTEZOMIB (B), DOXORUBICIN (DOX) AND DEXAMETHASONE (DEX, VBDD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS (PTS): RESULTS OF AN OPEN, NON-COMPARATIVE, PHASE I/II INVESTIGATOR INITIATED TRIAL (IIT)
PO-331	F. Patriarca	LONG TERM FOLLOW-UP OF A DONOR VERSUS NO DONOR COMPARISON IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE AFTER PREVIOUS AUTOTRANSPLANT	M. Mohty	OUTCOME OF TREATMENT FOR FIRST VERSUS LATER RELAPSE IN MULTIPLE MYELOMA (MM) IN REAL-WORLD CLINICAL PRACTICE: RESULTS FROM THE THIRD INTERIM ANALYSIS OF THE MULTINATIONAL, NON-INTERVENTIONAL, OBSERVATIONAL EMMOS STUDY
PO-332	S.J. Harrison	PHASE 1 CLINICAL TRIAL OF MARIZOMIB (MRZ, NPI-0052) IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING MULTIPLE MYELOMA: STUDY NPI-0052-102 (NCT00629473) FINAL RESULTS	M. Offidani	OPTIMAL SEQUENTIAL THERAPY IN FIRST LINE AND FIRST RELAPSE OF MM: A POST-HOC ANALYSIS
PO-333	P.L. Clemens	PHARMACOKINETICS OF DARATUMUMAB FOLLOWING INTRAVENOUS INFUSION IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM) AFTER PRIOR PROTEASOME INHIBITOR (PI) AND IMMUNOMODULATORY DRUG (IMiD) TREATMENT	A. López	PATTERNS OF RELAPSE AND OUTCOME OF ELDERLY MULTIPLE MYELOMA PATIENTS TREATED WITH VMP OR VTP AS INDUCTION FOLLOWED BY MAINTENANCE WITH VT OR VP IN THE SPANISH GEM2005MAS65 TRIAL
PO-334	V. Montefusco	BORTEZOMIB VERSUS LENALIDOMIDE IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE: FIRST INTERIM ANALYSIS OF A PHASE III STUDY	G. Koehne	CD34-SELECTED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH RELAPSED, HIGH-RISK MULTIPLE MYELOMA
PO-335	J.F. San-Miguel	IMPACT OF TREATMENT DURATION AND DOSING ON EFFICACY AND SAFETY IN A PHASE 3 STUDY OF PANOBINOSTAT PLUS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RE-	A. Khot	A PHASE 1, OPEN-LABEL, DOSE ESCALATION, SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF A FIRST IN CLASS POL1 INHIBITOR (CX-5461) IN PATIENTS WITH ADVANCED HAEMATOLOGIC MALIGNANCIES (HM)
			F. Rezzonico	HIGHLY PROLONGED OVERALL SURVIVAL FOLLOWING REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA IN THE NEW DRUGS ERA

PO-349	A.M. Cornelison	DURABLE REMISSION AND SURVIVAL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	PO-362	D.M. Sullivan	OVERCOMING PROTEASOME INHIBITOR RESISTANCE IN MULTIPLE MYELOMA USING THE XPO1: INHIBITOR SELINEXOR
PO-350	E.C. Scott	AUTOPHAGY AND MTOR INHIBITION AS MECHANISMS FOR COMBATING CHEMORESISTANCE TO STANDARD CHEMOTHERAPY: FINAL RESULTS OF A PHASE I STUDY OF INFUSIONAL CYCLOPHOSPHAMIDE (CY), PULSE DEXAMETHASONE (DEX), RAPAMYCIN (RAPA) AND HYDROXYCHLOROQUINE (HCQ)	PO-363	L. Rosiñol	POSTTRANSPLANT CYCLOPHOSPHAMIDE AS GVHD PROPHYLAXIS IN PATIENTS WITH MULTIPLE MYELOMA. EXPERIENCE OF A SINGLE CENTER
PO-351	G. Koehne	WILMS' TUMOR 1 PROTEIN IS HIGHLY EXPRESSED ON MALIGNANT PLASMA CELLS AND PROVIDES A NOVEL TARGET FOR IMMUNOTHERAPEUTIC APPROACHES	PO-364	A. Gozzetti	INTRAVENOUS BORTEZOMIB (IV) INFUSION AFTER NON RESPONSE TO SUBCUTANEOUS BORTEZOMIB (SQ) ADMINISTRATION CAN INDUCE TRANSITORY RESPONSES IN MULTIPLE MYELOMA PATIENTS: IS SOME PATIENT MORE SENSITIVE TO THE IV BORTEZOMIB?
PO-352	S. Danhof	EFFICACY AND SAFETY OF PRE-APPROVAL CARFILZOMIB-BASED THERAPY OF MULTIPLE MYELOMA IN DAILY PRACTICE – EXPERIENCE FROM A GERMAN ACADEMIC CENTER	PO-365	P. Forsberg	A PHASE I STUDY OF THE ADDITION OF HIGH-DOSE LENALIDOMIDE TO MELPHALAN CONDITIONING FOR AUTOLOGOUS STEM-CELL TRANSPLANT IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
PO-353	H. Quach	LOWER DOSE LENALIDOMIDE-DEXAMETHASONE IS LESS TOXIC AND DOES NOT COMPROMISE EFFICACY FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE AGED ≥60 YEARS AND/OR WITH RENAL IMPAIRMENT AND/OR WITH THROMBOCYTOPENIA	PO-366	C. Cerchione	BENDAMUSTINE-BORTEZOMIB-DESAMETASONE (BVD) IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REGIONAL REAL-LIFE EXPERIENCE
PO-354	H. Jiang	SAR650984 (SAR) DIRECTLY INDUCES MULTIPLE MYELOMA (MM) CELL DEATH VIA LYOSOMAL-ASSOCIATED AND APOPTOTIC PATHWAYS, WHICH IS FURTHER ENHANCED BY POMALIDOMIDE	PO-367	V.H. Jimenez Zepeda	POMALIDOMIDE-CONTAINING REGIMENS FOR THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
PO-355	C. Wang	VACCINE BASED IMMUNOTHERAPY AS A STRATEGY TO BYPASS DRUG RESISTANCE IN MULTIPLE MYELOMA	PO-368	J. Hou	EFFICACY AND SAFETY OF LENALIDOMIDE (LEN) PLUS LOW-DOSE DEXAMETHASONE (DEX; RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) ACCORDING TO DISEASE STAGE (INTERNATIONAL STAGING SYSTEM [ISS]): RESULTS FROM THE MM-021 TRIAL AND MM-024 EXTENDED ACCESS PROGRAM (EAP)
PO-356	M.M. Majumder	IDENTIFICATION OF PRECISION TREATMENT STRATEGIES FOR HIGH RISK MULTIPLE MYELOMA BY EX VIVO DRUG SENSITIVITY TESTING	PO-369	T. Facon	TWO RANDOMIZED OPEN-LABEL STUDIES OF DARATUMUMAB (DARA) PLUS STANDARD OF CARE TREATMENT VERSUS STANDARD OF CARE ALONE IN PATIENTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA (MM) INELIGIBLE FOR HIGH-DOSE THERAPY: 54767414MMY3007 (ALCYONE) AND 54767414MMY3008 (MAIA)
PO-357	S. Trudel	A PHASE 1/2 TRIAL OF THE INSULIN GROWTH FACTOR 1 RECEPTOR (IGF-1R) INHIBITOR, LINSITINIB IN COMBINATION WITH BORTEZOMIB (BTZ) AND DEXAMETHASONE (DEX) FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)	PO-370	M.H. Qazilbash	MYELOABLATIVE TIMED SEQUENTIAL BUSULFAN IS SAFE IN PATIENTS WITH RELAPSED OR HIGH-RISK MULTIPLE MYELOMA
PO-358	S. Striffler	THE CONTRIBUTION OF A THIRD AUTOLOGOUS STEM CELL TRANSPLANT IN THE ERA OF NOVEL AGENTS: FAVOURABLE OVERALL SURVIVAL AND IMPROVEMENT OF EXHAUSTED BONE MARROW FUNCTION	PO-371	C. Cerchione	PEGYLATED LIPOSOMAL DOXORUBICINE, CYCLOPHOSPHAMIDE AND DEXAMETASONE (CED): A NEW OPPORTUNITY IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA
PO-359	N. Maciocia	OUTCOME OF POMALIDOMIDE THERAPY IN RELAPSED / REFRACTORY MYELOMA: A UK MULTI-CENTRE EXPERIENCE	PO-372	H. Handa	LENALIDOMIDE EXPAND CD3+CD56+ T CELL CYTOKINE INDUCED KILLER (CIK) CELLS IN VIVO IN MULTIPLE MYELOMA PATIENTS
PO-360	A. García-Guiñón	RENAL RESPONSE IN PATIENTS (PTS) WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) AND SEVERE RENAL IMPAIRMENT (RI): INTERIM DATA FROM A LARGE OBSERVATIONAL, PROSPECTIVE STUDY	PO-373	L. Cesini	ORAL CYCLOPHOSPHAMIDE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURING LENALIDOMIDE-DEXAMETHASONE TREATMENT: RESULTS OF A RETROSPECTIVE MULTICENTER ANALYSIS
PO-361	A. Liço	LENALIDOMIDE LONG-TERM NEUROTOXICITY: NEUROPHYSIOLOGICAL FOLLOW-UP STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MYELOMA	PO-374	A. Leivas	MULTIPLE INFUSIONS OF AUTOLOGOUS ACTIVATED AND EXPANDED NATURAL KILLER CELLS: A NEW THERAPEUTIC OPTION FOR MULTIPLE MYELOMA

PO-375	R. Kaedbey	A SINGLE CENTRE RETROSPECTIVE ANALYSIS OF THE ADDITION OF CLARITHROMYCIN (BIAIXIN) TO LENALIDOMIDE AND DEXAMETHASONE (LEN-DEX) DURING TIME OF PROGRESSIVE DISEASE IN PATIENTS WITH MULTIPLE MYELOMA (MM)	PO-388	Y. Aydin	CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA, SINGLE CENTER EXPERIENCE
PO-376	S.Y. Huang	A NON-INTERVENTIONAL OBSERVATIONAL REGISTRY OF PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH LENALIDOMIDE (LEN) AND DEXAMETHASONE (DEX) IN TAIWAN	PO-389	Z. Shen	ECONOMIC ANALYSIS OF LENALIDOMIDE/DEXAMETHASONE (LEN/DEX) VS. BORTEZOMIB (BORT) FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN CHINA
PO-377	J. Lu	A NON-INTERVENTIONAL, OBSERVATIONAL REGISTRY OF ADULT PATIENTS WITH MULTIPLE MYELOMA TREATED WITH REVLMID (LENALIDOMIDE) IN CHINA: INTERIM ANALYSIS	PO-390	S.N. Lim	BORTEZOMIB PRETREATMENT BEFORE ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED MULTIPLE MYELOMA
PO-378	I. Isola	PACE AS SALVAGE THERAPY FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA	PO-391	A. Alegre	MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE (MGRS): RAPID HEMATOLOGICAL AND RENAL COMPLETE RESPONSE TO BORTEZOMIB
PO-379	D.W. Sborov	COMBINATION CARFILZOMIB AND THE VIRAL ONCOLYTIC AGENT REOLYSIN IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: A PILOT STUDY INVESTIGATING VIRAL PROLIFERATION	PO-392	L. Yu	SAFETY OF LENALIDOMIDE (LEN) PLUS LOW-DOSE DEXAMETHASONE (DEX; RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH PRIOR THALIDOMIDE (THAL) AND BORTEZOMIB (BORT): SUBANALYSIS OF THE MM-024 EXTENDED ACCESS PROGRAM (EAP)
PO-380	A.T. Firatli Tuğlular	POST-AUTHORIZATION SAFETY OF LENALIDOMIDE + DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN TURKEY	PO-393	K.S. Jung	THE EFFICACY AND SAFETY OF LENALIDOMIDE IN MULTIPLE MYELOMA WITH SEVERE RENAL IMPAIRMENT
PO-381	O. Miles	EFFICACY OF POMALIDOMIDE AFTER PROGRESSION FOLLOWING LENALIDOMIDE AND BORTEZOMIB-A MULTICENTER RETROSPECTIVE STUDY	PO-394	M.I. Pereira	A NATIONAL EXPERIENCE OF THE EFFICACY AND SAFETY OF LONG-TERM TREATMENT WITH LENALIDOMIDE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA
PO-382	J.A. Chadwick	LENALIDOMIDE FOR HEAVILY PRETREATED RELAPSED/REFRACTORY MYELOMA COHORT IN NORTHWEST UNITED KINGDOM (UK) – EFFICACY & TOLERABILITY: HIGH RESPONSE & LOW SECOND MAJORITY RATES	PO-395	R. Haznedar	IS URINE IMMUNOFIXATION ELECTROPHORESIS NECESSARY FOR MONITORING MYELOMA PATIENTS WHO HAS UNDERGONE HEMATOPOIETIC STEM CELL TRANSPLANTATION
PO-383	C. João	EFFECTIVENESS OF LENALIDOMIDE TREATMENT IN PATIENTS WITH VERY SEVERE RENAL IMPAIRMENT AND RELAPSED MULTIPLE MYELOMA	PO-396	C. Montes Gaisan	POMALIDOMIDE IN REFRACTORY MULTIPLE MYELOMA (MMRR): A SINGLE CENTER EXPERIENCE
PO-384	J. Kwon	EFFICACY AND TOXICITY OF THE COMBINATION THERAPY OF THALIDOMIDE, ALKYLATING AGENT, AND CORTICOSTEROID FOR RELAPSED/REFRACTORY MYELOMA PATIENTS: A REPORT FROM THE KOREAN MULTIPLE MYELOMA WORKING PARTY (KMMWP) RETROSPECTIVE STUDY	PO-397	H.J. Kim	METRONOMIC CHEMOTHERAPY OF THALIDOMIDE, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
PO-385	Z. Cai	IMPACT OF IMMUNOGLOBULIN (IG) D SUBTYPE ON THE EFFICACY AND SAFETY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): MM-021 TRIAL	PO-398	G. Mele	SYNCHRONOUS LOCALIZATIONS OF MULTIPLE MYELOMA IN 3 DIFFERENT SITES (ETHMOIDAL SINUSES, TESTICLES AND SKIN) DURING THE COURSE OF MULTIPLE MYELOMA (MM) THERAPY
PO-386	J. Richter	POMALIDOMIDE BASED THERAPY IN PATIENTS WITH SEVERE RENAL IMPAIRMENT	PO-399	S. Ongoren	IGD MULTIPLE MYELOMA, DESCRIPTIVE REPORT OF EIGHT CASES, SINGLE CENTRE EXPERIENCE
PO-387	M. Garcia-Fortes	INCIDENCE OF THROMBOSIS IN MULTIPLE MYELOMA PATIENTS TREATED WITH LENALIDOMIDE-DEXAMETHASONE IN OUR CENTER. THE INFLUENCE OF RISK FACTORS	PO-400	M. Steinbach	CASE REPORT: POMALIDOMIDE AS CONSOLIDATION THERAPY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANT

7. Nurse Session

POSTER SESSION

PO-401	A. Bernardini	MANAGEMENT OF TOXICITIES ASSOCIATED WITH CARFILZOMIB: AN UPDATE OF THE ITALIAN EXPERIENCE
PO-402	C. Woodrow	DEVELOPING SAFE HAEMATOLOGICAL MONITORING GUIDELINES FOR PATIENTS WITH MYELOMA ON BORTEZOMIB BASED REGIMENS
PO-403	C. Marrin	HOW A PATIENT SATISFACTION SURVEY CAN ENHANCE A MYELOMA OUTPATIENT CLINIC
PO-404	H. King	ARE THE MYELOMA POPULATION COMPUTER LITERATE? – SQUASHING THE SNAIL MAIL
PO-405	J. Helwlett	DEVELOPING A NURSE LED, HOLISTIC NEEDS ASSESSMENT CLINIC FOR MYELOMA PATIENTS

ABSTRACT REVIEWERS

Nizar J.	Bahlis	Calgary, Canada
Sara	Bringham	Torino, Italy
Raymond L.	Comenzo	Boston, USA
Meletios A.	Dimopoulos	Athens, Greece
Angela	Dispenzieri	Rochester, USA
Beth	Fainan	Cleveland, USA
Francesca	Gay	Torino, Italy
Irene M.	Ghobrial	Boston, USA
Andrzej	Jakubowiak	Chicago, USA
Tracy	King	Sydney, Australia
Shaji K.	Kumar	Rochester, USA
Sagar	Lonial	Atlanta, USA
Valeria	Magarotto	Torino, Italy
Maria-Victoria	Mateos	Salamanca, Spain
Giampalolo	Merlini	Pavia, Italy
Fortunato	Morabito	Cosenza, Italy
Gareth J.	Morgan	Little Rock, USA
Pellegrino	Musto	Rionero in Vulture (PZ), Italy
Massimo	Offidani	Ancona, Italy
Stefania	Oliva	Torino, Italy
Torben	Plesner	Vejle, Denmark
Noopur	Raje	Boston, USA
S. Vincent	Rajkumar	Rochester, USA
Andrew	Spencer	Melbourne, Australia
A. Keith	Stewart	Scottsdale, USA
Elena	Zamagni	Bologna, Italy
Sonja	Zweegman	Amsterdam, The Netherlands

ACKNOWLEDGEMENTS

PLATINUM SPONSORS



GOLD SPONSORS




SILVER SPONSORS



Bristol-Myers Squibb



CONTRIBUTORS



ORGANIZING SECRETARIAT

Studio ER Congressi

Via Marconi, 36 - 40122 Bologna, Italy

Phone. +39 051 4210559 - Fax +39 051 4210174

E-mail: imw2015@thetriumph.com

www.ercongressi.it

www.imw2015.it